MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Cancer Chemotherapy and Pharmacology' source. Wed, 08 Feb 2012 08:41:20 +0100 http://www.medworm.com/index.php?rid=5666755&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0278091141022671%2F Conclusion  Gemcitabine in combination with vinorelbine is active and safe in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-012-1830-1Authors Ningning Dong, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Medical Oncology Department, Peking University School of Oncology, Beijing Cancer Hospital & Institute, 52 Fucheng Rd, Beijing, 100142 ChinaMingyu Wang, Chemotherapy Department, Shandong Tumor Hospital and Institute, 440 Jiyan Rd, Jinan, 250117 ChinaHuiqing Li, Epidemiology Department, Institute of Basic Medicine, Shandong Academy of Medical Sciences, 18877 Jingshi Rd, Jinan, 250062 ChinaYongchun Cui, Clinical Tr... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5666755 Fri, 03 Feb 2012 17:12:25 +0100 5666755 http://www.medworm.com/index.php?rid=5666758&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdp68w397w2237020%2F Conclusions  When KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations are concomitant, up to 96.0% of NSCLC patients unlikely to respond to TKIs can be identified, and they represented independent negative prognostic factors. Comprehensive molecular dissection of EGFR signaling pathways should be considered to select advanced NSCLC patients for TKIs therapies. Content Type Journal ArticleCategory Original ArticlePages 1-11DOI 10.1007/s00280-012-1829-7Authors V. Ludovini, Medical Oncology Division, S. Maria della Misericordia Hospital, 1, Via G. Dottori, 06132 Perugia, ItalyF. Bianconi, Department of Electronic and Information Engineering, University of Perugia, Perugia, ItalyL. Pistola, Medical Oncology Division, S. Maria della Misericordia Hospital, 1, Via G. Dott... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5666758 Thu, 02 Feb 2012 18:11:01 +0100 5666758 http://www.medworm.com/index.php?rid=5666757&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm46r69j2h82848vn%2F Conclusions  This in vitro assay predicted primary platinum resistance, without misclassification of sensitive OC patients, and the results were significantly associated with PFS. We suggest that samples from primary tumor and metastatic samples have different responses to chemotherapy and that exposure to chemotherapy might induce in vitro platinum resistance. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-012-1835-9Authors Thea Eline Hetland, Departement of Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, NorwayJanne Kærn, Departement of Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, NorwayMartina Skrede, Departement of Pathology, Norwegian Radium Hospital... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5666757 Thu, 02 Feb 2012 18:11:01 +0100 5666757 http://www.medworm.com/index.php?rid=5666756&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw311gq829n6666r0%2F Conclusions  CP-31398 is bioavailable and has a relatively long elimination half-life, which supports the achievement of plasma steady-state levels with a once daily dosing regimen. CP-31398 exhibits a dramatically high volume of distribution, which is consistent with its tissue concentrations being much higher than corresponding plasma levels. It is accumulated in colon tumor tissues, albeit at lower concentrations than found in liver, skin, and colon. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00280-011-1811-9Authors Izet M. Kapetanovic, Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd., Rm. 2116, Bethesda, MD 20892, USAMiguel Muzzio, Life Sciences Group,... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5666756 Thu, 02 Feb 2012 18:11:01 +0100 5666756 http://www.medworm.com/index.php?rid=5666759&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv2665220xw75522v%2F Conclusions  Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy. Content Type Journal ArticleCategory Original ArticlePages 1-11DOI 10.1007/s00280-012-1834-xAuthors Guo Bing Zhang, Department of Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qing Chun Street, Hangzhou, 310003 People’s Republic of ChinaJian Chen, Department of Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qing Chun Street, Hangzhou, 310003 People’s Republic of Chin... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5666759 Thu, 02 Feb 2012 18:11:00 +0100 5666759 http://www.medworm.com/index.php?rid=5659397&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb6l3m543716542t6%2F Conclusions  GD acquired similar survival with platinum-based regimens in first-line treatment of advanced NSCLC. Platinum-based regimens had an advantage in TTP and ORR with more grade 3–4 nausea/vomiting, anemia, neutropenia and febrile neutropenia compared with GD. Content Type Journal ArticleCategory Original ArticlePages 1-11DOI 10.1007/s00280-012-1833-yAuthors Yong Yu, Department of Respiratory Medicine, The Second Affiliated Hospital of Soochow University, No. 1055 SanXiang Road, Suzhou, 215004 ChinaXun Xu, Department of Respiratory Medicine, The Second Affiliated Hospital of Soochow University, No. 1055 SanXiang Road, Suzhou, 215004 ChinaZiyan Du, Department of Respiratory Medicine, The Second Affiliated Hospital of Soochow University, No. 1055 SanXiang Roa... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5659397 Wed, 01 Feb 2012 17:10:03 +0100 5659397 http://www.medworm.com/index.php?rid=5659398&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj07842u76v4t3133%2F Conclusion  Midostaurin demonstrated a good safety profile in healthy volunteers, with no prolonged cardiac repolarization or other changes on the electrocardiogram. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-012-1825-yAuthors Adam del Corral, Novartis Oncology, East Hanover, NJ, USACatherine Dutreix, Novartis Oncology, Basel, SwitzerlandAlice Huntsman-Labed, Novartis Oncology, Basel, SwitzerlandSebastien Lorenzo, Novartis Oncology, Basel, SwitzerlandJoel Morganroth, ERT, East Bridgewater, NJ, USARobert Harrell, Osborne Research Center, LLC, Little Rock, AR, USAYanfeng Wang, Novartis Oncology, East Hanover, NJ, USA Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemothe... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5659398 Tue, 31 Jan 2012 16:48:29 +0100 5659398 http://www.medworm.com/index.php?rid=5659399&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4h63096281567052%2F Conclusions  Rifampin and ketoconazole both have a clinically meaningful effect on the pharmacokinetics of ridaforolimus. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1819-1Authors Mark Stroh, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USAJohn Palcza, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USAJacqueline McCrea, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USASabrina Marsilio, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USASheila Breidinger, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USADeborah Panebianco, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USAAmy Johnson-Levonas, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USAWalter K. Kraft, Department of Pharmacology and Experimental... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5659399 Tue, 31 Jan 2012 07:06:12 +0100 5659399 http://www.medworm.com/index.php?rid=5638075&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F446180hrp5l600w3%2F Conclusion  The present results imply that MRP5 index may hold a prognostic role in patients with GBM. Content Type Journal ArticleCategory Short CommunicationPages 1-5DOI 10.1007/s00280-012-1832-zAuthors George A. Alexiou, Department of Neurosurgery, University Hospital of Ioannina, Ioannina, GreeceAnna Goussia, Department of Pathology, University Hospital of Ioannina, Ioannina, GreeceSpyridon Voulgaris, Department of Neurosurgery, University Hospital of Ioannina, Ioannina, GreeceAndreas D. Fotopoulos, Department of Nuclear Medicine, University Hospital of Ioannina, Ioannina, GreeceGeorge Fotakopoulos, Department of Neurosurgery, University Hospital of Ioannina, Ioannina, GreeceAntigoni Ntoulia, Department of Pathology, University Hospital of Ioannina, Ioannina, GreeceA... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5638075 Wed, 25 Jan 2012 18:14:31 +0100 5638075 http://www.medworm.com/index.php?rid=5647041&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb483608628253g17%2F Conclusion  Erlotinib might be an alternative option for patients resistant to cytotoxic chemotherapy even in those with EGFR wild-type NSCLC. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00280-012-1831-0Authors Takashi Kobayashi, Comprehensive Cancer Center, Division of Clinical Oncology, Shinshu University School of Medicine, Shinshu University Hospital, 3-1-1, Asahi Matsumoto, Matsumoto, 390-8621 JapanTomonobu Koizumi, Comprehensive Cancer Center, Division of Clinical Oncology, Shinshu University School of Medicine, Shinshu University Hospital, 3-1-1, Asahi Matsumoto, Matsumoto, 390-8621 JapanToshihide Agatsuma, First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, JapanMasanori Yasuo, First Departmen... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5647041 Wed, 25 Jan 2012 18:14:30 +0100 5647041 http://www.medworm.com/index.php?rid=5638076&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3j88215652332760%2F Conclusions  Melatonin as an adjuvant therapy for cancer led to substantial improvements in tumor remission, 1-year survival, and alleviation of radiochemotherapy-related side effects. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-012-1828-8Authors Ye-min Wang, Department of Pharmacy, The First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, The City of Weihui, Xinxiang, Henan Province, ChinaBao-zhe Jin, Department of Surgery, The First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, The City of Weihui, Xinxiang, Henan Province, ChinaFang Ai, Department of Surgery, The First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, The City of Weihui, Xinxiang, Henan Province, C... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5638076 Tue, 24 Jan 2012 06:48:04 +0100 5638076 http://www.medworm.com/index.php?rid=5638077&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj5n2v3236h5707nm%2F Conclusions  The PK profile of single-agent T-DM1 (3.6 mg/kg q3w) is predictable, well characterized, and unaffected by circulating levels of HER2 extracellular domain or residual trastuzumab. T-DM1 exposure does not correlate with clinical responses or key adverse events. Content Type Journal ArticleCategory Original ArticlePages 1-12DOI 10.1007/s00280-011-1817-3Authors Sandhya Girish, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USAManish Gupta, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USABei Wang, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USADan Lu, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USAIan E. Krop, Dana-Farber Cancer Institute, Boston, MA, USACharles L. Vogel, Sylvester Comprehensive Cancer... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5638077 Tue, 24 Jan 2012 06:48:02 +0100 5638077 http://www.medworm.com/index.php?rid=5638078&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh53387686417pk76%2F Discussion  Although ABCB1 3435 T/T was significantly associated with docetaxel-related neutropenia in our study population, polymorphism of pharmacogenetic genes related to docetaxel metabolism did not appear to be evidently associated with docetaxel-related adverse events. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1816-4Authors Kyu-pyo Kim, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Poongnap-dong, Songpa-gu, Seoul, 138-736 KoreaJin-Hee Ahn, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Poongnap-dong, Songpa-gu, Seoul, 138-736 KoreaSung-Bae Kim, Department of Oncology, Asan Medical Center, Univers... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5638078 Tue, 24 Jan 2012 06:48:00 +0100 5638078 http://www.medworm.com/index.php?rid=5619682&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa987336264622870%2F Conclusion  These findings indicate that TAp73 silencing is hallmark of GSC to maintain their chemoresistance phenotype. Thus, targeting TAp73 may provide a novel strategy to eradicating GSCs. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-012-1823-0Authors Xiaogang Hu, Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing, 400038 ChinaNan Wu, Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038 ChinaPeiyuan Xia, Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing, 400038 ChinaSicang Yu, Institute of Pathology, Southwest Hospital, Third Military Medical University, Chongqing, 400038 ChinaFengjun Sun, Department of Ph... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5619682 Thu, 19 Jan 2012 06:53:40 +0100 5619682 http://www.medworm.com/index.php?rid=5619683&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh89261n507k20h03%2F Conclusions  The GS group showed stronger anticancer activity than the G group, suggesting the need for a large randomized phase III study to confirm GS advantages in a specific subset. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-012-1822-1Authors Masato Ozaka, Department of Gastroenterology, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550 JapanYuji Matsumura, Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421 JapanHiroshi Ishii, Department of Gastroenterology, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550 JapanYasushi Omuro, Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-1... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5619683 Tue, 17 Jan 2012 07:12:28 +0100 5619683 http://www.medworm.com/index.php?rid=5608149&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn5w250937238w45k%2F Conclusions  Aprepitant altered the exposure of cyclophosphamide and DCE but not the active 4-OH metabolite, making it unlikely that aprepitant would change the clinical efficacy of cyclophosphamide. African Americans were also found to have altered PK compared with Caucasian patients. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1815-5Authors Christine M. Walko, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USAAustin J. Combest, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USAIvan Spasojevic, Duke Cancer Institute Clinical Pharmacology Laboratory, Duke University Medical Center, Durham, NC, USAAngela Y. C. Yu, UNC Eshelman School of Pharmacy, University of No... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5608149 Sat, 14 Jan 2012 16:42:36 +0100 5608149 http://www.medworm.com/index.php?rid=5596941&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5732v60u71t75718%2F Conclusions  We determined the RD of gemcitabine/cisplatin/S-1 combination therapy for advanced biliary tract cancer; we are proceeding to a phase II study to investigate the efficacy of this combination therapy for advanced biliary tract cancer. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1818-2Authors Masashi Kanai, Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, JapanEtsuro Hatano, Department of Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto, JapanSyogo Kobayashi, Department of Surgery, Graduate School of Medicine, Osaka University, Osaka, JapanYutaka Fujiwara, Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, JapanDaisuke Sakai, Department o... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5596941 Wed, 11 Jan 2012 17:51:05 +0100 5596941 http://www.medworm.com/index.php?rid=5596942&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl898722l7m163547%2F Conclusion  These data support the hypothesis that expression of UGT1A is critical for 5-methylselenocysteine to exert its protective effect against irinotecan-induced toxicity. Content Type Journal ArticleCategory Short CommunicationPages 1-5DOI 10.1007/s00280-011-1820-8Authors Shousong Cao, Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USAFarukh A. Durrani, Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USAYoucef M. Rustum, Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USAY. Eugene Yu, Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, Elm and Ca... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5596942 Wed, 11 Jan 2012 17:51:03 +0100 5596942 http://www.medworm.com/index.php?rid=5596944&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk4311p45848557j9%2F Conclusion  In the present phase I study of AMR administered weekly to previously treated lung cancer patients, the maximum tolerated dose and RD were 65 and 60 mg/m2, respectively. The best response rate was 15.4%, and adverse events with this schedule were tolerable. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-7DOI 10.1007/s00280-011-1812-8Authors Chiyoe Kitagawa, Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001 JapanHideo Saka, Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001 JapanShigehisa Kajikawa, Department of Respiratory Medicine, Nagoya University Graduate Schoo... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5596944 Wed, 11 Jan 2012 17:51:02 +0100 5596944 http://www.medworm.com/index.php?rid=5596943&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu05x73m106124178%2F Conclusion  Collectively, this study demonstrates Csn3 as an oncogene that regulates the tumorigenesis process in HCC cells. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1810-xAuthors Yong-sheng Yu, Department of Infectious Diseases, Sixth People’s Hospital, Shanghai Jiaotong University, Yishan Road 600, Shanghai, 200233 ChinaZheng-hao Tang, Department of Infectious Diseases, Sixth People’s Hospital, Shanghai Jiaotong University, Yishan Road 600, Shanghai, 200233 ChinaQing-chun Pan, Department of Infectious Diseases, Sixth People’s Hospital, Shanghai Jiaotong University, Yishan Road 600, Shanghai, 200233 ChinaXiao-hua Chen, Department of Infectious Diseases, Sixth People’s Hospital, Shanghai Jiaotong University, Yishan Road... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5596943 Wed, 11 Jan 2012 17:51:02 +0100 5596943 http://www.medworm.com/index.php?rid=5596945&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy241g406n1p78439%2F Conclusions  Ridaforolimus was shown to inhibit its intended target, mTOR, in PBMCs, skin, and tumors. In PBMCs and skin, inhibition was observed at all dose levels tested, thus supporting but not driving the selection of a recommended phase 2 dose. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-9DOI 10.1007/s00280-011-1813-7Authors Lori Berk, ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USAMonica M. Mita, Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center, San Antonio, TX, USAJeff Kreisberg, Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center, San Antonio, TX, USACamille L. Bedrosian, ARIAD Pharmace... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5596945 Mon, 09 Jan 2012 19:37:50 +0100 5596945 http://www.medworm.com/index.php?rid=5571957&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fyu331u7j89042q40%2F Conclusions  RD-RCHOP chemotherapy is well tolerated and effective in elderly patients with DLBCL. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1814-6Authors Ho-Jin Shin, Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, 1-10, Ami-Dong, Seo-Gu, Busan, KoreaJoo Seop Chung, Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, 1-10, Ami-Dong, Seo-Gu, Busan, KoreaMoo-Kon Song, Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, 1-10, Ami-Dong, Se... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5571957 Wed, 04 Jan 2012 06:59:55 +0100 5571957 http://www.medworm.com/index.php?rid=5571958&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft04x85360162n5l2%2F Conclusion  This study defined the substantial excretion of ASA404, mainly as metabolites, in both urine (over half of the dose) and faeces (about one-third of the dose) after intravenous administration. Two novel metabolites were identified that were not reported by previous studies using nonradioactive techniques. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00280-011-1809-3Authors M. J. McKeage, Cancer Clinical Pharmacology Research Group, Auckland Cancer Society Research Centre, School of Medical Sciences, Faculty of Medical and Health Sciences, The University of Auckland, 85 Park Road, Grafton, Auckland, 1142 New ZealandP. C. Fong, Cancer Clinical Pharmacology Research Group, Auckland Cancer Society Research Centre, School of Medic... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5571958 Mon, 02 Jan 2012 16:46:11 +0100 5571958 http://www.medworm.com/index.php?rid=5571959&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F23889u8k71046577%2F Conclusions  Population-based models characterized the PK for all three drugs. bWBC was a significant covariate for etoposide and cytarabine and showed a trend for daunorubicin. Linking the significant bWBC relationships and the relationship between kidney function and etoposide clearance to clinical end points would support dose individualization. Patients with above-normal creatinine clearances and high bWBC may receive sub-optimal treatment due to elevated etoposide clearances. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1800-zAuthors Mikkel Krogh-Madsen, Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Jagtvej 160, 2100 Copenhagen, DenmarkBrendan Bender, Departm... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5571959 Mon, 02 Jan 2012 16:46:10 +0100 5571959 http://www.medworm.com/index.php?rid=5559433&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa7h803343k003161%2F Conclusions  Increased exposure to AMG 386 was associated with improved clinical outcomes in recurrent ovarian cancer, supporting the evaluation of a higher dose in future studies. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00280-011-1787-5Authors Jian-Feng Lu, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, CA 91320, USAErik Rasmussen, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, CA 91320, USABeth Y. Karlan, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USAIgnace B. Vergote, Department of Obstetrics and Gynecology, University Hospital Leuven, Herestraat 49, 3000 Leuven, BelgiumLynn Navale, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, CA 91320, ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5559433 Sat, 31 Dec 2011 06:37:17 +0100 5559433 http://www.medworm.com/index.php?rid=5559434&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc801l55pg115vu16%2F Conclusions  The pharmacokinetics of GEM and S-1 indicate that changing the dose of adjuvant chemotherapy based on the operation method for biliary cancers is reasonable. We believe that this regimen will be established as an effective adjuvant chemotherapy for biliary cancer in the future. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1805-7Authors Takeshi Takahara, Department of Surgery, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, JapanHiroyuki Nitta, Department of Surgery, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, JapanYasushi Hasegawa, Department of Surgery, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5559434 Fri, 30 Dec 2011 07:10:07 +0100 5559434 http://www.medworm.com/index.php?rid=5552028&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd762020687253644%2F In this study, we explored whether UHRF1 can be a therapeutic target for human breast carcinoma. We successfully constructed the tumor-specific shRNA expression vector driven by survivin promoter targeting UHRF1 gene. The tumor-specific RNA interference system efficiently and specifically knocked down UHRF1 expression, induced the apoptosis of tumor cells, and enhanced chemosensitivity of tumor cells to cisplatinum, but not in normal cells in vitro and in vivo. Therefore, the survivin promoter-driving shRNA expression system targeting UHRF1 may play a vital and potential role for the treatment of specificity and high efficacy in human breast carcinomas. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1801-yAuthors Lin Fang, Department of Cli... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5552028 Wed, 28 Dec 2011 16:45:19 +0100 5552028 http://www.medworm.com/index.php?rid=5552027&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm62559374605qqm8%2F Conclusion  Combination of bortezomib, gemcitabine, and liposomal doxorubicin is well tolerated, but with a lower recommended phase II dose in elderly patients, and demonstrated antitumor activity, especially in T-cell and small cell histology malignancies. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00280-011-1808-4Authors G. S. Falchook, Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program)-Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USAM. Duvic, Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USAD. S. Hong, Divis... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5552027 Wed, 28 Dec 2011 16:45:19 +0100 5552027 http://www.medworm.com/index.php?rid=5552030&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe48016u43x26t361%2F Conclusions  The predicted non-specific clearance of MFGR1877A in humans is similar to typical human IgG1 antibodies and will be verified in a Phase 1 study. The projected human efficacious dose and regimen appear to be achievable in patients. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1807-5Authors Amrita V. Kamath, Department of Pharmacokinetics and Pharmacodynamics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USADan Lu, Department of Pharmacokinetics and Pharmacodynamics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USAPriyanka Gupta, Department of Pharmacokinetics and Pharmacodynamics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USADenise Jin, Department of Pharmacokinetics and P... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5552030 Tue, 27 Dec 2011 16:50:37 +0100 5552030 http://www.medworm.com/index.php?rid=5552029&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn3440779l2k112q3%2F Conclusions  The PK of MEHD7945A was nonlinear in mouse and monkey in the dose range tested. The nonspecific clearance in monkey was approximately twofold higher than typical humanized IgG1 antibodies. The projected human efficacious dose and dose regimen appear to be achievable in patients. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1806-6Authors Amrita V. Kamath, Department of Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, CA 94080, USADan Lu, Department of Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, CA 94080, USAPriyanka Gupta, Department of Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, CA 94080, USADenise Jin, Department of Pharm... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5552029 Tue, 27 Dec 2011 16:50:37 +0100 5552029 http://www.medworm.com/index.php?rid=5552031&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg02524523un14102%2F Conclusions  Afatinib displayed a complete mass balance with the main route of excretion via feces. Afatinib undergoes minimal metabolism. Content Type Journal ArticleCategory Original ArticlePages 1-11DOI 10.1007/s00280-011-1803-9Authors Peter Stopfer, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse, 88400 Biberach an der Riss, GermanyKristell Marzin, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse, 88400 Biberach an der Riss, GermanyHans Narjes, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse, 88400 Biberach an der Riss, GermanyDietmar Gansser, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse, 88400 Biberach an der Riss, GermanyMehdi Shahidi, Boehringer Ingelheim, Bracknell, UKMartina Uttereuther-Fischer, B... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5552031 Mon, 26 Dec 2011 16:44:10 +0100 5552031 http://www.medworm.com/index.php?rid=5544158&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx27r48380536k405%2F Conclusion  Based on the results of this study, a value close to the targeted AUC can be obtained in a hemodialysis patient with cancer when carboplatin is administered at a dose determined based on the Calvert formula. These results may be useful to achieve a targeted AUC in hemodialysis patients. A certain amount of carboplatin can be eliminated by performing hemodialysis in an early phase when protein binding ratio is low after transition to the elimination phase to enable stable the concentration. Content Type Journal ArticleCategory Short CommunicationPages 1-4DOI 10.1007/s00280-011-1802-xAuthors Mikako Hiraike, Department of Pharmacy, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Kumamoto, Kumamoto 860-0008, JapanYoichi Hiraki, Departme... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5544158 Thu, 22 Dec 2011 12:50:07 +0100 5544158 http://www.medworm.com/index.php?rid=5537462&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw073x32217384x72%2F Conclusions  AMP423 has pro-oxidant effects similar to imexon, has greater cytotoxic potency in vitro, and has anti-tumor activity in hematologic tumors in vivo. Content Type Journal ArticleCategory Original ArticlePages 1-11DOI 10.1007/s00280-011-1784-8Authors Robert T. Dorr, The University of Arizona Cancer Center, College of Medicine, 1515 N. Campbell Avenue, Tucson, AZ 85724-5024, USALee Wisner, The University of Arizona Cancer Center, College of Medicine, 1515 N. Campbell Avenue, Tucson, AZ 85724-5024, USABetty K. Samulitis, The University of Arizona Cancer Center, College of Medicine, 1515 N. Campbell Avenue, Tucson, AZ 85724-5024, USATerry H. Landowski, The University of Arizona Cancer Center, College of Medicine, 1515 N. Campbell Avenue, Tucson, AZ 85724-5... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5537462 Tue, 20 Dec 2011 16:47:30 +0100 5537462 http://www.medworm.com/index.php?rid=5537461&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe1281n456558j559%2F Conclusion  Our results showed that CIP-13F effectively inhibited LLC growth and pulmonary metastasis in mice and suggested that CIP-13F is a potential drug for the treatment for cancers with positive APN/CD13 expression. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00280-011-1799-1Authors Ke-Ling Pei, Key Laboratory for Rare Disease of Shandong Province, Department of Pharmacology, Institute of Materia Medica, Shandong Academy of Medical Sciences, Jinan, 250062 ChinaYi Yuan, Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan, 250012 ChinaSan-Hai Qin, Key Laboratory for Rare Disease of Shandong Province, Department of Pharmacology, Institute of Materia Medica, Shandong Academy of Medical Sciences, J... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5537461 Tue, 20 Dec 2011 16:47:30 +0100 5537461 http://www.medworm.com/index.php?rid=5524121&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flh4282456qw34535%2F Conclusions  The pharmacokinetic profile of sunitinib appears similar between a powder formulation and published data using capsules. The powder formulation allows patients unable to swallow capsules to receive sunitinib. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1798-2Authors Steven G. DuBois, Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143-0106, USASuzanne Shusterman, Department of Pediatrics, Dana-Farber Cancer Institute, Children’s Hospital Boston, Harvard Medical School, Boston, MA, USAJoel M. Reid, Department of Pharmacology, Mayo College of Medicine, Rochester, MN, USAAshish M. Ingle, Children’s Oncology Group Operations Center, Arcadia, CA, USACharlotte H. Ahe... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5524121 Sat, 17 Dec 2011 16:43:43 +0100 5524121 http://www.medworm.com/index.php?rid=5494595&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe972267188417777%2F Conclusion  The combination of enzastaurin 500 mg daily and erlotinib 150 mg daily is well tolerated and does not alter the pharmacokinetics of the individual drugs, with clinical activity seen. A phase II trial of this combination has been initiated in patients with advanced-stage NSCLC. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1792-8Authors Sukhmani K. Padda, Department of Medicine, Division of Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USAYelena Krupitskaya, Department of Medicine, Division of Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USALaveena Chhatwani, Department of Medicine, Division of Oncology, Stanford University, 875 Blake Wilbu... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5494595 Sat, 10 Dec 2011 16:55:07 +0100 5494595 http://www.medworm.com/index.php?rid=5486437&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv6062230088856q1%2F Conclusions  S-1 monotherapy is effective and well-tolerated treatment for previously treated advanced NSCLC. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1795-5Authors M. Wada, Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato Minami-ku, Sagamihara, Kanagawa 252-0374, JapanM. Yamamoto, Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato Minami-ku, Sagamihara, Kanagawa 252-0374, JapanS. Ryuge, Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato Minami-ku, Sagamihara, Kanagawa 252-0374, JapanY. Nagashima, Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato Minami-ku, Sagami... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5486437 Wed, 07 Dec 2011 12:54:49 +0100 5486437 http://www.medworm.com/index.php?rid=5486438&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb851028x660577w5%2F Conclusion  Clinicians should be aware that administration of an acid suppressant such as famotidine, nizatidine, and lansoprazole can decrease the absorption of dasatinib from the gastrointestinal tract, thereby resulting in a significant decrease in the plasma concentration of dasatinib. The combination of dasatinib and an acid suppressant requires careful therapeutic drug monitoring of the dasatinib plasma concentration to ensure effective patient exposure to the drug. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00280-011-1797-3Authors Naoto Takahashi, Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, JapanMasatomo Miura, Department of Pharmacy, Akita University Hospital, 1-... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5486438 Tue, 06 Dec 2011 17:01:19 +0100 5486438 http://www.medworm.com/index.php?rid=5486439&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft71r063086021823%2F Abstract  The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors. Content Type Journal ArticleCategory CommentaryPages 1-3DOI 10.1007/s00280-011-1796-4Authors J. Lee Villano, Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 840 S. Wood St. Rm. 839 (M/C 713), Chicago, IL 60612, USANathalie Letarte, Fa... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5486439 Tue, 06 Dec 2011 17:01:18 +0100 5486439 http://www.medworm.com/index.php?rid=5486440&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr37jm620725342t7%2F Conclusions  Single-dose administration of dacomitinib plus DM was safe and well tolerated in HVs and resulted in a significant increase in systemic exposures of DM in extensive metabolizers. No effect was observed on the pharmacokinetics of dacomitinib. Drug–drug interaction may occur when dacomitinib is concomitantly administered with therapeutic agents metabolized by cytochrome P450 (CYP) 2D6. Administration of drugs which are highly dependent on CYP2D6 metabolism may require dose adjustment, or substitution with an alternative medication. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1793-7Authors Carlo L. Bello, Pfizer Oncology, 235 East 42nd Street, New York, NY 10017, USARobert R. LaBadie, Pfizer PharmaTherapeutics, N... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5486440 Tue, 06 Dec 2011 17:01:16 +0100 5486440 http://www.medworm.com/index.php?rid=5486442&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff067803550817367%2F Conclusions  Ridaforolimus was well tolerated up to a dose of 40 mg in Japanese patients. Preliminary evidence of antitumor activity was observed for patients with solid tumors. Further investigation at this dose is warranted. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-7DOI 10.1007/s00280-011-1788-4Authors Yoshitaka Seki, Division of Internal Medicine, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, JapanNoboru Yamamoto, Division of Internal Medicine, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, JapanYosuke Tamura, Division of Internal Medicine, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, JapanYasushi Goto, Division of Internal Medicine, National Cancer Center... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5486442 Mon, 05 Dec 2011 17:33:57 +0100 5486442 http://www.medworm.com/index.php?rid=5486441&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp24589r156153t11%2F Abstract Purpose  Dexrazoxane is an established treatment option in extravasation of the classic anthracyclines such as doxorubicin, epirubicin, and daunorubicin. However, it is not known whether the protection against the devastating tissue injuries extends into extravasation with new types of anthracyclines, the anthracenediones, or the liposomal pegylated anthracycline formulations. We therefore tested the antidotal efficacy of dexrazoxane against extravasation of amrubicin, mitoxantrone, and liposomal pegylated doxorubicin in mice. Methods  A total of 80 female B6D2F1 mice were tested in an established mouse extravasation model. The mice had experimental extravasations of amrubicin, mitoxtanrone, and Caelyx and were immediately hereafter treated with ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5486441 Mon, 05 Dec 2011 17:33:57 +0100 5486441 http://www.medworm.com/index.php?rid=5476154&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F26728215300l15v8%2F Conclusions  These findings suggest a tumor-specific action of DIF-1 on oral carcinoma cells. Thus, interfering with E2F1 and TS transcription, DIF-1 potentiates TS enzymatic inhibitors. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1790-xAuthors Andrea Elio Sprio, Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga, 10043 Orbassano, ItalyFederica Di Scipio, Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga, 10043 Orbassano, ItalyPaolo Ceppi, Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga, 10043 Orbassano, ItalyPaolina Salamone, Department of Clinical and Biological Sciences, University of Tur... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5476154 Sat, 03 Dec 2011 16:49:38 +0100 5476154 http://www.medworm.com/index.php?rid=5468411&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F37t3g2013402t828%2F Conclusions  Tumor heterogeneity and probably also previous systemic treatment may be an obstacle for correct interpretation of EGFR status in NSCLC. Heterogeneity regarding EGFR mutations is probably rare and previously reported intra and intertumor heterogeneity may be due to methodological issues. In the current and future clinical scenario with many different options for systemic treatment both as 2nd line and beyond, it is increasingly important to further elucidate the role extent of chemotherapy-induced changes in biomarker expression for proper use of biomarkers in order to customize treatment and thus improve prognosis. Content Type Journal ArticleCategory Mini ReviewPages 1-11DOI 10.1007/s00280-011-1791-9Authors Jan Nyrop Jakobsen, Department of Oncology,... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5468411 Wed, 30 Nov 2011 18:42:27 +0100 5468411 http://www.medworm.com/index.php?rid=5456981&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk1605g5xu456n137%2F Conclusions  The combination of docetaxel and 17-AAG was well tolerated in adult patients with solid tumors, although patient intolerance to the DMSO formulation precluded further dose escalation. The recommended phase II dose is docetaxel 70 mg/m2 and 17-AAG 500 mg/m2. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-9DOI 10.1007/s00280-011-1789-3Authors Gopa Iyer, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USAMichael J. Morris, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USADana Rathkopf, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USASusan F. Slovin, Department of Me... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5456981 Mon, 28 Nov 2011 16:59:35 +0100 5456981 http://www.medworm.com/index.php?rid=5456982&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ful5n687327722l30%2F Conclusions  Nilotinib was well tolerated in these patients with advanced GIST. Accrual was halted due to insufficient clinical benefit. However, nilotinib may provide benefit to specific subsets of advanced GIST with exon 17 mutations. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00280-011-1785-7Authors C. Cauchi, Regina Elena Institute for Cancer Research, Rome, ItalyN. Somaiah, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAP. F. Engstrom, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAS. Litwin, Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USAM. Lopez, Regina Elena Institute for Cancer Research, Rome, ItalyJ. Lee, Protocol Management Office, Fox C... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5456982 Sat, 26 Nov 2011 16:48:37 +0100 5456982 http://www.medworm.com/index.php?rid=5449525&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm4w3652683j12802%2F Conclusion  This combination regimen of FGS is active and well tolerated in patients with Gem-refractory PC. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1786-6Authors Chigusa Morizane, Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 JapanTakuji Okusaka, Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 JapanHideki Ueno, Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 JapanShunsuke Kondo, Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5449525 Fri, 25 Nov 2011 17:57:53 +0100 5449525 http://www.medworm.com/index.php?rid=5449526&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv7055k55077g2p81%2F Conclusions  Amrubicin appears to have a distinct mode of action that overcomes typical anthracycline resistance mechanisms. Therefore, amrubicin may be useful in the treatment of anthracycline-refractory or anthracycline-resistant tumors. Content Type Journal ArticleCategory Original ArticlePages 1-12DOI 10.1007/s00280-011-1782-xAuthors Vidya Mamidipudi, Translational Development Department, Celgene Corporation, 1500 Owens St. Suite 600, San Francisco, CA 94158, USATao Shi, Celgene Corporation, 4550 Town Centre Court, San Diego, CA 92121, USAHelen Brady, Celgene Corporation, 4550 Town Centre Court, San Diego, CA 92121, USASekhar Surapaneni, Drug Metabolism and Pharmacokinetics Department, Celgene Corporation, 86 Morris Ave., Summit, NJ 07901, USARajesh Chopra, Transl... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5449526 Fri, 25 Nov 2011 17:57:52 +0100 5449526 http://www.medworm.com/index.php?rid=5449527&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa1878705159m3845%2F Conclusions  Variability in the AUClast and C max values for the capecitabine was consistent with the known PK profile of capecitabine and fell within established limits. Concurrent trastuzumab therapy is unlikely to alter the PK or safety profile of capecitabine or cisplatin in Japanese patients with HER2-positive AGC. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1783-9Authors Taroh Satoh, Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Osaka, JapanYasushi Omuro, Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, JapanYasutsuna Sasaki, Department of Medical Oncology, Saitama International Medical Center–Co... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5449527 Thu, 24 Nov 2011 17:45:15 +0100 5449527 http://www.medworm.com/index.php?rid=5449528&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd757735883523175%2F Conclusion  Thalidomide and lenalidomide penetrate into the CSF after oral administration of clinically relevant doses. Plasma exposure to lenalidomide was similar in our model to that observed in studies involving children who have brain tumors. These results support further development of lenalidomide for the treatment of central nervous system malignancies. Content Type Journal ArticleCategory Original ArticlePages 1-5DOI 10.1007/s00280-011-1781-yAuthors Jodi A. Muscal, Texas Children’s Cancer Center, Baylor College of Medicine, 1102 Bates Street, Suite 1220, Houston, TX 77030, USAYongkai Sun, Celgene Corporation, Summit, NJ, USAJed G. Nuchtern, Department of Surgery, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, USARobert C. Dauser, Depa... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5449528 Wed, 23 Nov 2011 16:39:25 +0100 5449528 http://www.medworm.com/index.php?rid=5440341&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2m15m031025702p7%2F Conclusions  Oral 3-AP is well tolerated and has an MTD similar to its intravenous form after accounting for the oral bioavailability. Oral 3-AP is associated with a modest clinical benefit rate of 25% in our treated patient population with advanced solid tumors. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-9DOI 10.1007/s00280-011-1779-5Authors Joseph Chao, City of Hope Medical Center, Building room 4117, 1500 East Duarte Road, 91010 Duarte, CA, USATimothy W. Synold, City of Hope Medical Center, Building room 4117, 1500 East Duarte Road, 91010 Duarte, CA, USARobert J. Morgan, City of Hope Medical Center, Building room 4117, 1500 East Duarte Road, 91010 Duarte, CA, USACharles Kunos, Case Western Reserve University, Cleveland, OH, USAJeff Longmate, ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5440341 Mon, 21 Nov 2011 18:09:34 +0100 5440341 http://www.medworm.com/index.php?rid=5440342&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq603385m251r3668%2F Conclusions  This study suggests a role of nitric oxide in the pathogenesis of irinotecan-induced intestinal mucositis and also provides evidence for the participation of cytokines on iNOS induction. Content Type Journal ArticleCategory Original ArticlePages 1-12DOI 10.1007/s00280-011-1780-zAuthors Roberto César P. Lima-Júnior, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Rua Cel Nunes de Melo, 1315, Rodolfo Teófilo, Fortaleza, Ceará 60430-270, BrazilAline A. Figueiredo, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Rua Cel Nunes de Melo, 1315, Rodolfo Teófilo, Fortaleza, Ceará 60430-270, BrazilHelano C. Freitas, Department of Physiology and Pharmacology, Faculty of ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5440342 Sat, 19 Nov 2011 16:51:35 +0100 5440342 http://www.medworm.com/index.php?rid=5421609&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj548955405kgt554%2F Conclusions  MGMT status is a predictive factor for pCR with neoadjuvant anthracycline-based plus taxane combination chemotherapy, which may be helpful in the selection of appropriate NACT for Japanese patients with BLBC. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1777-7Authors Katsuya Nakai, Department of Breast Oncology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, JapanHiroyuki Mitomi, Department of Human Pathology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, JapanYimit Alkam, Department of Breast Oncology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, JapanAtsushi Arakawa, Department of Human Pathology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5421609 Mon, 14 Nov 2011 16:53:00 +0100 5421609 http://www.medworm.com/index.php?rid=5407128&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq465k602k221v6w7%2F Conclusions  The results presented in this study provide evidence that chidamide has potential applicability for the treatment of a variety of tumor types, either as a single agent or in combination therapies. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1766-xAuthors Zhi-Qiang Ning, Chipscreen Biosciences Ltd., Bio-Incubator 2-601, 1st Ave. of Gaoxin Road, Hi-Tech Industrial Park, Shenzhen, 518057 Guangdong, ChinaZhi-Bin Li, Chipscreen Biosciences Ltd., Bio-Incubator 2-601, 1st Ave. of Gaoxin Road, Hi-Tech Industrial Park, Shenzhen, 518057 Guangdong, ChinaMichael J. Newman, HUYA Bioscience International, 12531 High Bluff Drive Suite 138, San Diego, CA 92130, USASong Shan, Chipscreen Biosciences Ltd., Bio-Incubator 2-601, 1st Av... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5407128 Fri, 11 Nov 2011 12:48:55 +0100 5407128 http://www.medworm.com/index.php?rid=5407127&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F90034676r9g74535%2F Abstract  Tyrosine kinase inhibitors represent a class of targeted therapy that has proven to be successful for cancer treatment. Linifanib is a novel, orally active multi-targeted receptor tyrosine kinase (RTK) inhibitor that exhibits potent antitumor and antiangiogenic activities against a broad spectrum of experimental tumors and malignancies in patients. The compound is currently being evaluated in phase 2 and 3 clinical trials. To investigate the effectiveness of linifinib against gliomas and the mechanism of drug action, we characterized treatment-induced antitumor and antiangiogenic responses to linifanib in an orthotopic rat glioma model. The effect of linifanib treatment on tumor growth was determined by tumor volume assessment using anatomical magnetic resonance i... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5407127 Fri, 11 Nov 2011 12:48:55 +0100 5407127 http://www.medworm.com/index.php?rid=5407129&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F51672w7002511048%2F Conclusion  Recommended dose for Phase II was defined as 50 mg/day for Japanese patients; the same as for non-Japanese patients. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1738-1Authors H. Murakami, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777 JapanT. Tamura, National Cancer Center Hospital, Tokyo, JapanT. Takahashi, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777 JapanH. Nokihara, National Cancer Center Hospital, Tokyo, JapanT. Naito, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777 JapanY. Nakamura, Division of ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5407129 Wed, 09 Nov 2011 17:55:57 +0100 5407129 http://www.medworm.com/index.php?rid=5407130&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc3078t0005740q61%2F Content Type Journal ArticleCategory Letter to the EditorPages 1-2DOI 10.1007/s00280-011-1776-8Authors Fabio Farinati, Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, ItalyAnna Giacomin, Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, ItalyVeronica Vanin, Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, Italy Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5407130 Wed, 09 Nov 2011 17:55:56 +0100 5407130 http://www.medworm.com/index.php?rid=5407132&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb178608275r44v20%2F Conclusion  XELIRI and XELIRINOX regimens are feasible and warrant further investigation in combination with targeted therapy in metastatic colorectal cancer patients. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1764-zAuthors T. Mazard, Département d’Oncologie Médicale, CHU Saint Eloi, Montpellier, FranceM. Ychou, Département d’Oncologie Médicale, CHU Saint Eloi, Montpellier, FranceS. Thezenas, Département de Biostatistiques, Centre Val d’Aurelle, Montpellier, FranceS. Poujol, Département de Pharmacie et de Pharmacologie, Centre Val d’Aurelle, Montpellier, FranceF. Pinguet, Département de Pharmacie et de Pharmacologie, Centre Val d’Aurelle, Montpellier, FranceA. Thirion, Département de Recherche Clinique, Cent... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5407132 Tue, 08 Nov 2011 19:16:03 +0100 5407132 http://www.medworm.com/index.php?rid=5384565&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg1608g246226467q%2F Conclusions  The administration of bexarotene, paclitaxel, and carboplatin is feasible and safe; however, the increased bexarotene plasma concentrations and exposure warrant further investigation if this combination is to be utilized clinically. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-10DOI 10.1007/s00280-011-1770-1Authors Jordi Rodon, Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, TX, USACharlotte D. Jacobs, Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USAQuincy Chu, Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas H... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384565 Sat, 05 Nov 2011 17:10:18 +0100 5384565 http://www.medworm.com/index.php?rid=5384567&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff500803l8xu76302%2F Conclusions  A drug–drug interaction was seen in this trial with bexarotene co-administration leading to a significant reduction in the AUC of atorvastatin. The likely mechanism for this interaction is through induction of CYP3A4 by bexarotene given the role of this enzyme in the metabolism of atorvastatin. Knowledge of this interaction is important for optimizing lipid management with atorvastatin for patients receiving bexarotene. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-9DOI 10.1007/s00280-011-1772-zAuthors Heather A. Wakelee, Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USAChris H. Takimoto, Institute for Drug Development, Cancer Therap... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384567 Sat, 05 Nov 2011 17:10:17 +0100 5384567 http://www.medworm.com/index.php?rid=5384566&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp3712105p7158g83%2F Conclusions  Bexarotene does not substantially affect vinorelbine or cisplatin PK, and the combination is well tolerated. The results are consistent with the mechanisms of elimination of vinorelbine (high metabolic clearance) and cisplatin (non-enzymatic and renal elimination). Content Type Journal ArticleCategory Clinical Trial ReportPages 1-10DOI 10.1007/s00280-011-1771-0Authors Heather A. Wakelee, Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USAGary Middleton, St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UKDavid Dunlop, Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UKRodryg Ramlau, Poznan University of Medical Sciences, Poznan, ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384566 Sat, 05 Nov 2011 17:10:17 +0100 5384566 http://www.medworm.com/index.php?rid=5384568&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F71l412483126r1m2%2F Conclusions  Food produced minor changes in oral panobinostat exposure; thus, panobinostat can be given without regard to food intake in future clinical studies. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-8DOI 10.1007/s00280-011-1758-xAuthors Geoffrey I. Shapiro, Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USARichard Frank, Whittingham Cancer Center at Norwalk Hospital, Norwalk, CT, USAUday B. Dandamudi, Section of Clinical Pharmacology, Department of Medicine, Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH 03756, USAThomas Hengelage, Novartis Pharma AG, Basel, SwitzerlandLily Zhao, Novartis Oncology, East Hanover, NJ, USALucien Gaz... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384568 Sat, 05 Nov 2011 17:10:16 +0100 5384568 http://www.medworm.com/index.php?rid=5384569&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fkl62563518j59554%2F Conclusion  The probability to develop FN in patients who experience grade IV neutropenia was dependent on the myelosuppression time profile. Patients with a rapid neutrophil decline and high drug sensitivity had a higher probability to develop FN. Model-based parameter estimates were superior predictors over descriptive values such as the nadir or duration of neutropenia. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00280-011-1769-7Authors Emma K. Hansson, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 751 24 Uppsala, SwedenLena E. Friberg, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 751 24 Uppsala, Sweden Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print IS... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384569 Fri, 04 Nov 2011 16:56:23 +0100 5384569 http://www.medworm.com/index.php?rid=5384570&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh7256r4566p11n23%2F Conclusions  The combination of vinflunine and capecitabine is safe and showed promising antitumour activity in MBC patients who have failed prior anthracyclines and taxanes. Further clinical development of this combination is warranted. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1767-9Authors M. Campone, Centre René Gauducheau, Nantes-Saint-Herblain, FranceN. Isambert, Centre Georges-François Leclerc, Dijon, FranceE. Bourbouloux, Centre René Gauducheau, Nantes-Saint-Herblain, FranceH. Roché, Institut Claudius Regaud, Toulouse, FranceJ. Bonneterre, Centre Oscar Lambret, Lille, FranceG. Milano, Centre Antoine Lacassagne, Nice, FranceP. Fumoleau, Centre Georges-François Leclerc, Dijon, France Journal Cancer Chemother... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384570 Tue, 01 Nov 2011 16:51:39 +0100 5384570 http://www.medworm.com/index.php?rid=5384572&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0144l162463l75r4%2F Conclusion  The pharmacokinetic profiles of amrubicin and amrubicinol were clarified, and the subsequent PK–PD analyses indicate that the clearance of amrubicinol is the major determinant of neutropenia. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1768-8Authors Yoshinori Makino, Department of Pharmacy, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 JapanNoboru Yamamoto, Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 JapanHitoshi Sato, Clinical and Molecular Pharmacokinetics/Pharmacodynamics, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 JapanReiko Ando, Department of Ph... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384572 Mon, 31 Oct 2011 16:50:30 +0100 5384572 http://www.medworm.com/index.php?rid=5384571&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F88jk744777011w37%2F Conclusion  Brain metastases should be treated aggressively and independently of the primary site tumor especially if the performance status of the patient is good. The role of chemotherapy should be addressed in the context of clinical trials. Content Type Journal ArticleCategory Mini ReviewPages 1-13DOI 10.1007/s00280-011-1775-9Authors Athanassios P. Kyritsis, Neurosurgical Research Institute, University of Ioannina, 45110 Ioannina, GreeceSofia Markoula, Department of Neurology, School of Medicine, University of Ioannina, University Campus, 45110 Ioannina, GreeceVictor A. Levin, Professor Emeritus, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Journal Cancer Chemotherapy and PharmacologyOnline ISSN 143... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384571 Mon, 31 Oct 2011 16:50:30 +0100 5384571 http://www.medworm.com/index.php?rid=5384573&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb646r5460t8l3545%2F Conclusion  Results suggest that ridaforolimus can cross the blood–brain barrier in areas of tumor involvement, and may inhibit mTOR activity in advanced gliomas based on decreased pS6 levels. This perisurgical trial design should serve as a template for evaluating intratumoral pharmacokinetics and pharmacodynamics of other targeted agents in this patient population. Content Type Journal ArticleCategory Original ArticlePages 1-12DOI 10.1007/s00280-011-1773-yAuthors David A. Reardon, Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue—SW G460F, Boston, MA 02215, USAPatrick Y. Wen, Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center, 44 Binney Street, Shields Warren 430 D, Boston, MA 02115, USAW. K. Alfred Yung, Depa... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384573 Sun, 30 Oct 2011 05:37:54 +0100 5384573 http://www.medworm.com/index.php?rid=5384574&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9348237251k2w135%2F Conclusions  These findings provide a novel insight into the clinical application of TRAIL-induced apoptosis of HCC cells. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1763-0Authors Guan Wang, College of Life Sciences, Wuhan University, Wuhan, 430072 ChinaYao Zhan, College of Life Sciences, Wuhan University, Wuhan, 430072 ChinaHaiqing Wang, College of Life Sciences, Wuhan University, Wuhan, 430072 ChinaWenhua Li, College of Life Sciences, Wuhan University, Wuhan, 430072 China Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384574 Sat, 29 Oct 2011 05:50:22 +0100 5384574 http://www.medworm.com/index.php?rid=5384575&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg2t74n9v521705nl%2F Conclusion  Intrapleural paclitaxel is a safe and effective palliative treatment for MPE from breast and ovarian cancers and may be integrated with systemic chemotherapy. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-011-1765-yAuthors Giuseppe Lombardi, Medical Oncology 1, Istituto Oncologico Veneto—IRCCS, Padova, ItalyMaria Ornella Nicoletto, Medical Oncology 1, Istituto Oncologico Veneto—IRCCS, Padova, ItalyMilena Gusella, Department of Oncology, ULSS 18, Rovigo, ItalyPasquale Fiduccia, Medical Oncology 1, Istituto Oncologico Veneto—IRCCS, Padova, ItalyMaurizia Dalla Palma, Medical Oncology 1, Istituto Oncologico Veneto—IRCCS, Padova, ItalyAndrea Zuin, Division of Thoracic Surgery, Department of Cardio-Thoracic and Vascular... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384575 Sat, 29 Oct 2011 05:50:21 +0100 5384575 http://www.medworm.com/index.php?rid=5384576&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy1345551563u1742%2F Conclusions  In summary, following oral administration, lenalidomide is highly absorbed and bioavailable, metabolized minimally, and eliminated predominantly via urinary excretion in the unchanged form in humans. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1760-3Authors Nianhang Chen, Clinical Pharmacology, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07920, USALian Wen, ABC Laboratories, Columbia, MO, USAHenry Lau, Clinical Pharmacology, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07920, USASekhar Surapaneni, Nonclinical Development, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07920, USAGondi Kumar, Nonclinical Development, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07920, USA Journal Cancer Chem... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5384576 Sat, 29 Oct 2011 05:50:20 +0100 5384576 http://www.medworm.com/index.php?rid=5359963&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw68658053766706r%2F Conclusions  The results show an encouraging disease control rate, time to progression, and overall survival. The combination of sorafenib and 5-fluorouracil was feasible, and the side effects were manageable for patients carefully selected for liver function and performance status. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1753-2Authors Iacopo Petrini, Department of Oncology, Transplant and New Advances in Medicine, BIOS, University of Pisa, 67 Via Roma, 56126 Pisa, ItalyMonica Lencioni, Medical Oncology, Pisa University Hospital, Pisa, ItalyMiriam Ricasoli, Medical Oncology, Pisa University Hospital, Pisa, ItalyMauro Iannopollo, Medical Oncology, Pisa University Hospital, Pisa, ItalyCinzia Orlandini, Medical Oncology, Pisa... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5359963 Fri, 28 Oct 2011 06:06:00 +0100 5359963 http://www.medworm.com/index.php?rid=5346891&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp65v8144t3052n21%2F Conclusions  The novel CENP-E inhibitor, GSK923295, had dose-proportional pharmacokinetics and a low number of grade 3 or 4 adverse events. The observed incidence of myelosuppression and neuropathy was low. Further investigations may provide a more complete understanding of the potential for GSK923295 as an antiproliferative agent. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1756-zAuthors Vincent Chung, City of Hope Medical Center, 1500 East Duarte Road, Durate, CA 91010, USAElisabeth I. Heath, Karmanos Cancer Center, Detroit, MI, USAWilliam R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI, USABrendan M. Johnson, GlaxoSmithKline, Research Triangle Park, NC, USALyndon C. Kirby, GlaxoSmithKline, Research T... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5346891 Fri, 21 Oct 2011 15:59:43 +0100 5346891 http://www.medworm.com/index.php?rid=5346890&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp743t57561881334%2F Conclusions  While the addition of vorinostat to 5-FU resulted in 1 partial response and in some disease stabilizations, the limited activity does not warrant the unselected use of this combination in chemotherapy-refractory colorectal cancer. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1762-1Authors M. G. Fakih, Department of Medicine, University of Michigan, Ann Arbor, MI, USAA. Groman, Department of Biostatistics, University at Buffalo, Buffalo, NY, USAJ. McMahon, Clinical Research Services, Roswell Park Cancer Institute, Buffalo, NY, USAG. Wilding, Department of Biostatistics, University at Buffalo, Buffalo, NY, USAJ. R. Muindi, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Journal Cancer Ch... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5346890 Fri, 21 Oct 2011 15:59:43 +0100 5346890 http://www.medworm.com/index.php?rid=5346889&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8h043v00v1p78332%2F Conclusion  AGS-1C4D4 was well-tolerated and demonstrated linear PK. Despite preclinical differences in antibody-dependent cellular cytotoxicity, AGS-1C4D4 and AGS-PSCA have similar safety and PK profiles. The recommended Phase II dose is 48 mg/kg. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1759-9Authors Emmanuel S. Antonarakis, Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, CRB1-1M59, 1650 Orleans Street, Baltimore, MD 21231, USAMichael A. Carducci, Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, CRB1-1M59, 1650 Orleans Street, Baltimore, MD... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5346889 Fri, 21 Oct 2011 15:59:43 +0100 5346889 http://www.medworm.com/index.php?rid=5346892&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn02w30522g158862%2F Conclusions  Oxo exposure was reduced under fed compared to fasting condition. To increase the bioavailability of S-1, the administration of S-1 under fasting condition was more effective in the western countries. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1761-2Authors Max E. Scheulen, West German Cancer Center, University of Essen, Essen, GermanyKaku Saito, Taiho Pharma USA, Inc, 202 Carnegie Center, Suite 100, Princeton, NJ 08550, USARalf A. Hilger, West German Cancer Center, University of Essen, Essen, GermanyBastian Mende, West German Cancer Center, University of Essen, Essen, GermanyChristopher Zergebel, Taiho Pharma USA, Inc, 202 Carnegie Center, Suite 100, Princeton, NJ 08550, USADirk Strumberg, University of Bochum (M... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5346892 Fri, 21 Oct 2011 15:59:40 +0100 5346892 http://www.medworm.com/index.php?rid=5323661&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe723176080481484%2F Conclusions  Exposure to gefitinib did not increase consistently with increasing dose beyond gefitinib 1,500 mg once-weekly or twice-weekly. These data do not support further evaluation of gefitinib at high-dose schedules. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-8DOI 10.1007/s00280-011-1757-yAuthors Mitchell E. Gross, Center for Applied Molecular Medicine, University of Southern California Westside Cancer Center, Beverly Hills, CA, USALawrence Leichman, Comprehensive Cancer Center and Desert Regional Medical Center, Palm Springs, CA, USAElizabeth S. Lowe, AstraZeneca, Wilmington, DE, USAAlan Swaisland, AstraZeneca, Macclesfield, Cheshire, UKDavid B. Agus, Center for Applied Molecular Medicine, University of Southern California Westside C... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5323661 Sat, 15 Oct 2011 05:53:14 +0100 5323661 http://www.medworm.com/index.php?rid=5323662&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5353688831pt8365%2F Conclusions  Our findings first suggest that miR-200bc/429 cluster could play a role in the development of MDR in both gastric and lung cancer cell lines, at least in part by modulation of apoptosis via targeting BCL2 and XIAP. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1752-3Authors Wei Zhu, Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029 ChinaHuaguo Xu, Department of Clinical Laboratory, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029 ChinaDanXia Zhu, Department of Haematology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029 ChinaHui Zhi, Department of Oncology, First ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5323662 Thu, 13 Oct 2011 05:48:37 +0100 5323662 http://www.medworm.com/index.php?rid=5313882&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F87674k44x8505213%2F Conclusions  In patients with advanced solid malignancies, the MTD of sunitinib plus 500 mg/m2 pemetrexed was 37.5 mg/day (CDD schedule) or 50 mg/day (Schedule 2/1). The CDD schedule MTD was tolerable and demonstrated promising clinical benefit in NSCLC. Content Type Journal ArticleCategory Original ArticlePages 1-14DOI 10.1007/s00280-011-1755-0Authors L. Q. M. Chow, The Ottawa Hospital Cancer Centre, Ottawa, CanadaN. Blais, Centre de Lutte Contre le Cancer du CHUM, Montreal, CanadaD. J. Jonker, The Ottawa Hospital Cancer Centre, Ottawa, CanadaS. A. Laurie, The Ottawa Hospital Cancer Centre, Ottawa, CanadaS. G. Diab, Colorado Integrative Cancer Care, Aurora, CO, USAC. Canil, The Ottawa Hospital Cancer Centre, Ottawa, CanadaM. McWilliam, The Ottawa Hospi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5313882 Wed, 12 Oct 2011 05:42:48 +0100 5313882 http://www.medworm.com/index.php?rid=5313883&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9530ml9j12l87401%2F Conclusions  In preclinical drug development, primary tumor cells from patients can be used for the prediction of cancer diagnosis–specific activity and may aid in the selection of diagnoses for clinical trials. By using tumor and toxicity panels together, information about therapeutic index may be derived, which may be useful when choosing among drug candidates with similar tumor effects. Content Type Journal ArticleCategory Original ArticlePages 1-11DOI 10.1007/s00280-011-1746-1Authors Caroline Haglund, Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, SwedenAnna Åleskog, Division of Haematology, Department of Medical Sciences, Uppsala University, Uppsala, SwedenPeter Nygren, Division of Clinical Pharmacology, Depart... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5313883 Sun, 09 Oct 2011 05:36:30 +0100 5313883 http://www.medworm.com/index.php?rid=5313884&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn4q85q03154x145q%2F Conclusions  The coadministration of AEE788 and RAD001 in glioblastoma patients caused a clinically significant thrombocytopenia and a higher-than-expected RAD001 area under the curve concentration when dosed at 200 and 5 mg/day, respectively. After a dose reduction to AEE788 (150 mg/day) and RAD001 (5 mg qod), the combination appeared to be better tolerated. Content Type Journal ArticleCategory Short CommunicationPages 1-7DOI 10.1007/s00280-011-1754-1Authors David A. Reardon, Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, SW-460F, Boston, MA 02215, USATimothy Cloughesy, University of California, Los Angeles, Los Angeles, CA, USAJeremy Rich, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USAW. K. Alfred Yung,... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5313884 Sat, 08 Oct 2011 15:45:02 +0100 5313884 http://www.medworm.com/index.php?rid=5313885&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm7rq8576n600v345%2F Conclusions  Leucovorin rescue given after high-dose MTX probably accounts for the lack of influence of C677T polymorphism. To better define a role of RFC1 polymorphism on patients outcome, it would be worthwhile to perform a study on intracellular MTX level and RFC1 substrate binding affinities in different genotypes. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00280-011-1751-4Authors Patrizia Chiusolo, Department of Hematology, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, ItalySabrina Giammarco, Department of Hematology, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, ItalySilvia Bellesi, Department of Hematology, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, It... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5313885 Sat, 08 Oct 2011 15:45:01 +0100 5313885 http://www.medworm.com/index.php?rid=5296604&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9785746n33216422%2F Conclusions  None of the different genetic covariates nor plasma and intracellular exposure was predictive of the observed neurotoxicity in our pediatric population. Nevertheless, the heterozygote diplotype of ABCB1 appears to influence the intracellular accumulation of vincristine. Owing to the small sample size, further evaluations are needed in a larger patient cohort. Content Type Journal ArticleCategory Short CommunicationPages 1-6DOI 10.1007/s00280-011-1745-2Authors Romain Guilhaumou, Aix-Marseille Univ, CRO2, INSERM, UMR 911, 13385 Marseille, FranceCaroline Solas, Aix-Marseille Univ, CRO2, INSERM, UMR 911, 13385 Marseille, FranceVeronique Bourgarel-Rey, Aix-Marseille Univ, CRO2, INSERM, UMR 911, 13385 Marseille, FranceSylvie Quaranta, Laboratoire de Pharmacoci... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5296604 Tue, 04 Oct 2011 05:50:36 +0100 5296604 http://www.medworm.com/index.php?rid=5296605&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fglv88170035vg131%2F Conclusion  This oral absorption enhanced NEC may provide a practical formulation to conduct the correlative study of the PK of curcuminoids and their pharmacodynamics, e.g., hypomethylation activity in vivo. Content Type Journal ArticleCategory Original ArticlePages 1-11DOI 10.1007/s00280-011-1749-yAuthors Liu Zhongfa, College of Pharmacy, The Ohio State University, Room 152, Riffe Building, 500 W. 12th Avenue, Columbus, OH 43210, USAMing Chiu, College of Pharmacy, The Ohio State University, Room 152, Riffe Building, 500 W. 12th Avenue, Columbus, OH 43210, USAJiang Wang, College of Pharmacy, The Ohio State University, Room 152, Riffe Building, 500 W. 12th Avenue, Columbus, OH 43210, USAWei Chen, College of Pharmacy, The Ohio State University, Room 152, Riffe Building... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5296605 Tue, 04 Oct 2011 05:50:34 +0100 5296605 http://www.medworm.com/index.php?rid=5296606&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8774198224710517%2F Conclusions  A trimodal approach, consisting of a single cycle of induction chemotherapy, CRT containing capecitabine and cisplatin, and surgery, was feasible and effective in patients with resectable esophageal squamous cell carcinoma. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1750-5Authors Dong Hoe Koo, Department of Oncology, University of Ulsan College of Medicine, Esophageal Cancer Study Group (ECSG), Asan Medical Center, 86, Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736 KoreaSeung-Il Park, Department of Thoracic Surgery, University of Ulsan College of Medicine, Esophageal Cancer Study Group (ECSG), Asan Medical Center, Seoul, KoreaYong-Hee Kim, Department of Thoracic Surgery, University of Ulsan College of Medicine, Esop... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5296606 Tue, 04 Oct 2011 05:50:33 +0100 5296606 http://www.medworm.com/index.php?rid=5296607&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fyt4610q73t258026%2F Conclusions  These data show that the major DNA adducts formed by Debio 0507 are the dach-Pt-d(GpG) and dach-Pt-d(ApG) adducts and at equitoxic doses Debio 0507 and oxaliplatin form similar levels of dach-Pt-d(GpG) and dach-Pt-d(ApG) adducts. This suggests that the action mechanisms of Debio 0507 and oxaliplatin are similar at a cellular level. Content Type Journal ArticleCategory Original ArticlePages 1-13DOI 10.1007/s00280-011-1744-3Authors C. L. King, Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina, CB #7260, Genetic Medicine Building, Chapel Hill, NC 27599-7260, USAS. Ramachandran, Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina, CB #7260, Genetic Medicine Building, Chapel Hil... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5296607 Tue, 04 Oct 2011 05:50:32 +0100 5296607 http://www.medworm.com/index.php?rid=5285169&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw374r60950237mh1%2F Conclusions  TH-302 exhibited good safety, efficacy and pharmacokinetic properties in nonclinical species, translating into favorable properties in humans. Content Type Journal ArticleCategory Original ArticlePages 1-12DOI 10.1007/s00280-011-1741-6Authors Donald Jung, Department of Nonclinical and Clinical Pharmacology, Threshold Pharmaceuticals, Inc., 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USALin Lin, Department of Nonclinical and Clinical Pharmacology, Threshold Pharmaceuticals, Inc., 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USAHailong Jiao, Department of Medicinal Chemistry, Threshold Pharmaceuticals, Inc., South San Francisco, CA, USAXiaohong Cai, Department of Medicinal Chemistry, Threshold Pharmaceuticals, Inc., South San Fran... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5285169 Sat, 01 Oct 2011 06:45:04 +0100 5285169 http://www.medworm.com/index.php?rid=5285170&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk006461131087752%2F Conclusions  The combination of weekly docetaxel and fixed dose rate gemcitabine was tolerable and may be an active regimen in patients with previously treated advanced sarcoma. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1742-5Authors Eun Mi Lee, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-Dong Songpa-Gu, Seoul, 138-736 KoreaSun Young Rha, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KoreaJeeyun Lee, Division of Hematology and Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaKyong Hwa Park, Division of Hematology a... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5285170 Fri, 30 Sep 2011 05:53:14 +0100 5285170 http://www.medworm.com/index.php?rid=5273234&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy88g472558848451%2F Conclusions  The presence of food decreased the extent of absorption of selumetinib. It is recommended that for further clinical studies, selumetinib be taken on an empty stomach. Selumetinib demonstrated an acceptable safety profile in the advanced cancer population. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-10DOI 10.1007/s00280-011-1732-7Authors Suzanne Leijen, Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsPatricia M. M. B. Soetekouw, Division of Medical Oncology, Department of Internal Medicine, GROW—School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsT. R. Jeffry Evans, Translational Cancer Research, Beatson... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5273234 Wed, 28 Sep 2011 05:51:06 +0100 5273234 http://www.medworm.com/index.php?rid=5273235&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw315056178036262%2F Conclusions  BO-1051 induced both apoptosis and autophagy, and inhibition of autophagy significantly augmented the cytotoxic effect of BO-1051. Thus, a combination of BO-1051 and autophagic inhibitors offers a potentially new therapeutic modality for the treatment of malignant glioma. Content Type Journal ArticleCategory Original ArticlePages 1-13DOI 10.1007/s00280-011-1747-0Authors Pei-Ming Chu, Graduate Institutes of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROCLi-Hsin Chen, Institute of Pharmacology, National Yang-Ming University, Taipei, TaiwanMing-Teh Chen, Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, TaiwanHsin-I Ma, Graduate Institutes of Life Sciences, National Defense Medical Center, Taip... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5273235 Tue, 27 Sep 2011 05:46:35 +0100 5273235 http://www.medworm.com/index.php?rid=5260148&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2t658581628710u4%2F Conclusions  The sandwich chemoradiation protocol proved to be feasible with manageable toxicity. The patient outcome compared favorably with other adjuvant trials in preventing relapse, particularly distant relapse which is predictive of poor outcome. This multidisciplinary approach warrants further investigation in a larger randomized trial. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1731-8Authors Christian H. Brandts, Department of Medicine, Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Str. 33, 48149 Muenster, GermanyChristiane Schulz, Department of Medicine, Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Str. 33, 48149 Muenster, GermanyNormann Willich, Department of Ra... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5260148 Sat, 24 Sep 2011 05:42:46 +0100 5260148 http://www.medworm.com/index.php?rid=5260149&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb72747770jp70659%2F Conclusions  As rat ERRP protein is expected to generate an immune response in humans, we propose a hypothesis that a humanized version of ERRP has potential therapeutic value for cancer patients. Content Type Journal ArticleCategory Mini ReviewPages 1-4DOI 10.1007/s00280-011-1748-zAuthors Xian-Hua Fu, Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, People’s Republic of ChinaJun Li, Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5260149 Fri, 23 Sep 2011 05:54:32 +0100 5260149 http://www.medworm.com/index.php?rid=5260150&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F10430242xgn27772%2F Conclusions  The PK and safety profiles of erlotinib in patients with MHI were similar to those with AHF. As a result, a reduced starting dose of erlotinib in patients with MHI is not required and treatment should be guided by patients’ tolerability. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1733-6Authors Cindy L. O’Bryant, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Cancer Center, Mail Stop C238, 12850 East Montview Blvd., V20-1223, Aurora, CO 80045, USAPaul Haluska, Mayo Clinic, Rochester, MN, USALee Rosen, Premiere Oncology, Santa Monica, CA, USARamesh K. Ramanathan, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USABalaji Venugopal, Beatson Oncology Centre, University of Gla... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5260150 Thu, 22 Sep 2011 06:38:13 +0100 5260150 http://www.medworm.com/index.php?rid=5236797&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F16wnq3l027774t82%2F Conclusions  Ishibashi’s formula would be predictable and useful for estimating the individual dose of NDP. Content Type Journal ArticleCategory Original ArticlePages 1-5DOI 10.1007/s00280-011-1739-0Authors Shinya Sato, Department of Obstetrics and Gynecology, Tottori University, 36-1, Nishi-cho, Yonago City, Tottori 683 8504, JapanHiroyuki Fujiwara, Department of Obstetrics and Gynecology, Jichi Medical College, Kawachi-gun, Tochigi, JapanTetsuro Oishi, Department of Obstetrics and Gynecology, Tottori University, 36-1, Nishi-cho, Yonago City, Tottori 683 8504, JapanMuneaki Shimada, Department of Obstetrics and Gynecology, Tottori University, 36-1, Nishi-cho, Yonago City, Tottori 683 8504, JapanShizuo Machida, Department of Obstetrics and Gynecology, Jichi Medical Coll... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5236797 Thu, 15 Sep 2011 05:53:56 +0100 5236797 http://www.medworm.com/index.php?rid=5224741&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F247707h460166673%2F Conclusion  The phase II recommended dose is everolimus 10 mg/day (days 1–21) + cisplatin 20 mg/m2 (days 1, 8, and 15) of a 28-day cycle. PK data demonstrate dose-proportional increases in exposure, as previously described for everolimus monotherapy. Anti-tumor activity was observed in several tumor types. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1734-5Authors Matthew G. Fury, Department of Medicine, Head and Neck Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY 10021, USAEric Sherman, Department of Medicine, Head and Neck Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY 10021, USASofia Haqu... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5224741 Tue, 13 Sep 2011 05:56:36 +0100 5224741 http://www.medworm.com/index.php?rid=5224742&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh56582168n746206%2F Conclusions  It is important to recognize the various patterns of TKI-induced ILDs, which increase in incidence with the introduction of diverse types of molecularly targeted agents. Poor prognoses are expected when there is a short interval from the initiation of target therapy to the onset of ILD, acute interstitial pneumonia pattern of ILD, and preexisting pulmonary fibrosis. Content Type Journal ArticleCategory Mini ReviewPages 1-11DOI 10.1007/s00280-011-1737-2Authors Ji Hye Min, Deparment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaHo Yun Lee, Deparment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaHoyeong Lim, The Division of Hematology-Oncology, Depart... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5224742 Tue, 13 Sep 2011 05:56:35 +0100 5224742 http://www.medworm.com/index.php?rid=5224743&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F82961451u451m850%2F Conclusions  A lower IC50 of DT-IgG partially compensated for lower serum concentrations than bevacizumab and cetuximab, but may require higher doses for comparable efficacy as the combination. The model adequately predicted variations of tumor response at the DT-IgG doses tested and could be used for targeting specific tumor efficacies for future testing. Content Type Journal ArticleCategory Original ArticlePages 1-14DOI 10.1007/s00280-011-1713-xAuthors Selwyn J. Hurwitz, Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine/VA Medical Center, Medical Research # 151H, 1670 Clairmont Road, Decatur, GA 30300, USAHongzheng Zhang, Department of Hematology and Medical Oncology, Winship Cancer Insti... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5224743 Tue, 13 Sep 2011 05:56:33 +0100 5224743 http://www.medworm.com/index.php?rid=5224744&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu56712h588u75071%2F Conclusions  The low rates of GvHD, particularly in its chronic form, were encouraging, and further biomarker studies are warranted to optimize the fludarabine/Tbusulfan/rATG conditioning regimen. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-10DOI 10.1007/s00280-011-1736-3Authors Jeannine S. McCune, School of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195-7630, USAErica L. Woodahl, School of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195-7630, USATerry Furlong, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USABarry Storer, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAJoanne Wang, School of Pharmacy, University of Washington, Box 357630, ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5224744 Sat, 10 Sep 2011 15:48:27 +0100 5224744 http://www.medworm.com/index.php?rid=5207903&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw311q10784x13268%2F Conclusions  The RD for elacytarabine was 100 mg/m2/day, D1-5 and D8-12 q4w. The safety profile was comparable to the safety profiles reported in previous clinical studies with elacytarabine in solid tumours. Despite some longer-lasting disease stabilisations, two of them exceeding the previous progression-free interval, further investigations of elacytarabine in the ovarian cancer indication are not warranted. Content Type Journal ArticleCategory Clinical Trial ReportPages 1-7DOI 10.1007/s00280-011-1735-4Authors S. Pignata, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, Naples, EU, ItalyF. Amant, Leuven Cancer Institute, Gynaecological Oncology, Leuven, BelgiumG. Scambia, Università Cattolica del Sacro Cuore, Rome, ItalyR. Sorio, Centro di Rifer... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5207903 Fri, 09 Sep 2011 16:46:16 +0100 5207903 http://www.medworm.com/index.php?rid=5207904&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe2p7264j5h82n51t%2F Conclusion  The combination of erlotinib and 5-azacytidine was well tolerated with interesting clinical activity in lung, head and neck, and ovarian cancer. The recommended dose for phase II study is erlotinib 150 mg daily and 5-azacytidine 75 mg/m2 daily on days 1–4 and 15–18 of a 28-day cycle. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1729-2Authors Julie Bauman, Division of Hematology/Oncology, University of New Mexico Cancer Center, Albuquerque, NM, USAClaire Verschraegen, Division of Hematology/Oncology, University of Vermont, Burlington, VT, USASteven Belinsky, Lovelace Respiratory Research Institute, Lung Cancer Program, Albuquerque, NM, USACarolyn Muller, Division of Gynecology Oncology, University of New Mexi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5207904 Thu, 08 Sep 2011 06:10:50 +0100 5207904 http://www.medworm.com/index.php?rid=5207905&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F67838739r664lh67%2F Conclusions  The results of this study confirm that triple negative, luminal B and HER2-enriched phenotypes identified by IHC are of adverse prognostic value in high-risk breast cancer patients treated with dose-dense sequential adjuvant chemotherapy. Content Type Journal ArticleCategory Original ArticlePages 1-14DOI 10.1007/s00280-011-1730-9Authors P. Skarlos, Department of Radiotherapy, Agios Savvas Cancer Hospital, Athens, GreeceC. Christodoulou, Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, GreeceK. T. Kalogeras, Translational Research Section, Hellenic Cooperative Oncology Group, Data Office, Athens, GreeceA. G. Eleftheraki, Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, GreeceM. Bobos, Laboratory of M... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5207905 Thu, 08 Sep 2011 06:10:49 +0100 5207905 http://www.medworm.com/index.php?rid=5175469&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F28088745g313773h%2F Conclusions  The RP2D of KOS-1584 is 36 mg/m2. The lack of severe neurologic toxicity, diarrhea, neutropenia, or hypersensitivity reactions; favorable pharmacokinetic profile; and early evidence of activity support further evaluation. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1724-7Authors Elaine T. Lam, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USASanjay Goel, Montefiore-Einstein Center for Cancer Care, Bronx, NY, USALarry J. Schaaf, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAGillian F. Cropp, Kosan Biosciences, Inc., Hayward, CA, USAAlison L. Hannah, Kosan Biosciences, Inc., Hayward, CA, USAYiqing Zhou, Kosan Biosciences, Inc., Hayward, CA, USABarbara McCracken, T... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5175469 Fri, 26 Aug 2011 16:16:34 +0100 5175469 http://www.medworm.com/index.php?rid=5175470&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F172138722471273h%2F Conclusion  The all-oral combination of metronomic CTX plus capecitabine is an effective and convenient and well-tolerated regimen for MBC. (ClinicalTrials.gov number, NCT00589901). Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1728-3Authors Zhonghua Wang, Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, 270 Dongan Road, Shanghai, 200032 ChinaJingsong Lu, Department of Breast Surgery, Cancer Hospital of Fudan University, Shanghai Medical College, Shanghai, ChinaShiangjiin Leaw, Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, 270 Dongan Road, Shanghai, 200032 ChinaXiaonan Hong, Department of Medical Oncology, Cancer Hospital of Fudan Unive... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5175470 Fri, 26 Aug 2011 16:16:33 +0100 5175470 http://www.medworm.com/index.php?rid=5161031&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F473215v5k1833t53%2F Conclusions  This study did not find any clinically meaningful effects of thalidomide on the pharmacokinetics of irinotecan or its metabolites. Content Type Journal ArticleCategory Short CommunicationPages 1-4DOI 10.1007/s00280-011-1727-4Authors Jacqueline Ramírez, Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Avenue, MC2115, Chicago, IL 60637, USAKehua Wu, Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Avenue, MC2115, Chicago, IL 60637, USALinda Janisch, Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Avenue, MC2115, Chicago, IL 60637, USATheodore Karrison, Department of Health Studies, University of Chicago, Chicago, IL 606... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5161031 Mon, 22 Aug 2011 16:00:16 +0100 5161031 http://www.medworm.com/index.php?rid=5161030&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc72u81333223u15p%2F In this study, we tested in vitro co-administration of the antineoplastic agents cisplatin or paclitaxel with probenecid, an anion channel inhibitor, in a panel of cancer cell lines to determine the cytotoxicity and synergistic effects of these drug combinations. In addition, we measured the clonogenicity and apoptotic index in these cells. We observed a synergistic interaction between probenecid and the chemotherapeutic agents, and increasing doses of probenecid resulted in a significant decrease in the effective doses of the chemotherapeutic agents. For the antineoplastic agent and probenecid combinations, we found increased cell death, reduced colony formation, and a higher number of apoptotic cells, compared with treatment of cisplatin or paclitaxel alone. Further research is ne... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5161030 Mon, 22 Aug 2011 16:00:16 +0100 5161030 http://www.medworm.com/index.php?rid=5161032&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft37k2t6x2210q313%2F Conclusion  The combination of gemcitabine with docetaxel and capecitabine is feasible and exhibits satisfactory degree of activity in patients with advanced pancreatic cancer, deserving further exploration. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1717-6Authors N. Xenidis, Department of Medical Oncology, University General Hospital of Alexandroupolis, Dragana, 68100 Alexandroupolis, Thrace, GreeceL. Chelis, Department of Medical Oncology, University General Hospital of Alexandroupolis, Dragana, 68100 Alexandroupolis, Thrace, GreeceK. Amarantidis, Department of Medical Oncology, University General Hospital of Alexandroupolis, Dragana, 68100 Alexandroupolis, Thrace, GreeceE. Chamalidou, Department of Medical Oncology, Univers... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5161032 Fri, 19 Aug 2011 15:53:06 +0100 5161032 http://www.medworm.com/index.php?rid=5161034&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk762133551x50273%2F Conclusions  Weekly administration of nab-paclitaxel was well tolerated up to 100 mg/m2 by heavily pretreated patients. For MBC patients, 150 mg/m2 nab-paclitaxel as a first-line therapy was well tolerated. Dose reduction due to neuropathy allows multiple cycles of treatment. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00280-011-1726-5Authors Masashi Ando, Department of Breast and Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045 JapanKan Yonemori, Department of Breast and Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045 JapanNoriyuki Katsumata, Department of Breast and Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tok... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5161034 Fri, 19 Aug 2011 06:40:43 +0100 5161034 http://www.medworm.com/index.php?rid=5161033&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu56q628522322033%2F Conclusions  Cediranib 20 mg/day in combination with cisplatin and S-1 or capecitabine was tolerable, with no new toxicities identified, and showed preliminary evidence of antitumour activity. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00280-011-1723-8Authors Taroh Satoh, Kinki University School of Medicine, Osaka, JapanYasuhide Yamada, National Cancer Centre Hospital, Tokyo, JapanKei Muro, Aichi Cancer Centre Hospital, Aichi, JapanHidetoshi Hayashi, Kinki University School of Medicine, Osaka, JapanYasuhiro Shimada, National Cancer Centre Hospital, Tokyo, JapanDaisuke Takahari, Aichi Cancer Centre Hospital, Aichi, JapanKeisei Taku, Shizuoka Cancer Centre, Shizuoka, JapanTakako Eguchi Nakajima, St. Marianna University School of Medi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5161033 Fri, 19 Aug 2011 06:40:43 +0100 5161033 http://www.medworm.com/index.php?rid=5161035&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg1537814p2647ppr%2F Conclusions  GTX is an active regimen in patients previously treated with gemcitabine for mPC. Better performance status and >75% drop in pretreatment CA 19-9 were associated with longer survival. The number of prior regimens did not predict for survival duration. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00280-011-1705-xAuthors Hassan K. Dakik, Duke University Medical Center, Durham, NC, USADaniel J. Moskovic, Baylor College of Medicine, Houston, TX, USAPeter J. Carlson, Baylor College of Medicine, Houston, TX, USAEric P. Tamm, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 426, Houston, TX 77030, USAWei Qiao, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 426, Houston, TX 7... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5161035 Thu, 18 Aug 2011 05:59:58 +0100 5161035 http://www.medworm.com/index.php?rid=5161037&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx238l774h8007571%2F Conclusions  This case reports for the first time the feasibility of trabectedin therapy in a hemodialyzed patient. Given the rising incidence of cancer in patients with end-stage renal disease, it is crucial to provide data that improve the management of anticancer drugs in dialyzed patients. Content Type Journal ArticleCategory Short CommunicationPages 1-5DOI 10.1007/s00280-011-1718-5Authors Juliette Thariat, Department of Radiation Oncology/IBDC CNRS 6543, Centre Antoine Lacassagne, 33 Av. de Valombrose, 06189 Nice Cedex 2, FranceMarie-Christine Etienne-Grimaldi, Oncopharmacology Unit, EA 3836, Centre Antoine Lacassagne, Nice, FranceVincent Launay-Vacher, Service ICAR, Department of Nephrology, Hôpital Pitié-Salpetrière, Paris, FranceArturo Soto-Matos, Clinical... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5161037 Thu, 18 Aug 2011 05:59:55 +0100 5161037 http://www.medworm.com/index.php?rid=5161036&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F72j4071277484np6%2F Conclusions  The MTDs for the combination of bortezomib and temozolomide in patients not taking HEIAs are 1.3 and 200 mg/m2, respectively. The rate of bortezomib elimination in patients taking HEIAs was increased twofold. Additional trials are needed to better define the optimal dosing in such patients. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00280-011-1721-xAuthors J. Portnow, Department of Medical Oncology, City of Hope, 1500 East Duarte Road, Duarte, CA 91030, USAP. Frankel, Department of Medical Oncology, City of Hope, 1500 East Duarte Road, Duarte, CA 91030, USAS. Koehler, Department of Medical Oncology, City of Hope, 1500 East Duarte Road, Duarte, CA 91030, USAP. Twardowski, Department of Medical Oncology, City of Hope, 1... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5161036 Thu, 18 Aug 2011 05:59:55 +0100 5161036 http://www.medworm.com/index.php?rid=5131706&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp556328245421pgu%2F Content Type Journal ArticlePages 1-1DOI 10.1007/s00280-011-1720-yAuthors Velia D’Angelo, Naples, Italy Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5131706 Sat, 13 Aug 2011 06:15:37 +0100 5131706 http://www.medworm.com/index.php?rid=5131705&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy1k74t5883v6h737%2F Conclusion  Our findings provide evidence that the inhibition of Nrf2 activity by shRNA might be a promising therapeutic strategy to enhance the efficacy of anticancer drugs and thus can be applied further during the course of chemotherapy in the treatment of cervical cancer. Content Type Journal ArticlePages 1-10DOI 10.1007/s00280-011-1722-9Authors Xiangdong Ma, Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University, 17 Changle West Road, Xi’an, 710032 People’s Republic of ChinaJianfang Zhang, Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University, 17 Changle West Road, Xi’an, 710032 People’s Republic of ChinaShujuan Liu, Department of Obstetrics and Gynecology, Xijing Hospital, Four... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5131705 Sat, 13 Aug 2011 06:15:37 +0100 5131705 http://www.medworm.com/index.php?rid=5131707&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F81g1277pqg542258%2F Abstract  The fluoropyrimidines are commonly used in chemotherapeutic cancer medicine, but many patients still experience severe adverse side effects from these drugs. We observed a severe toxicity in a 50-year-old woman treated with capecitabine and docetaxel for a metastatic breast cancer. Since dihydropyrimidine dehydrogenase (DPD) is the main candidate for pharmacogenetic studies on 5-FU toxicity, the entire coding sequence and exon-flanking intronic regions of the DPYD gene were sequenced in the patient. None of the previously described deleterious variants were detected. Also, the haplotype-based analysis failed to reveal DPYD variations associated with 5-FU toxicity. We also evaluated the UH2/U ratio in plasma as an index of 5-FU pharmacokinetics. The UH2/U value did ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5131707 Thu, 11 Aug 2011 05:54:10 +0100 5131707 http://www.medworm.com/index.php?rid=5108968&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxu2432m2g6h701wr%2F Content Type Journal ArticlePages 1-2DOI 10.1007/s00280-011-1719-4Authors Elixabet Lopez–Lopez, Department of Genetics, Physic Anthropology and Animal Physiology, Faculty of Medicine and Dentistry, University of the Basque Country, Barrio Sarriena s/n, 48940 Leioa, SpainJavier Ballesteros, Department of Neurosciences, University of the Basque Country, Leioa, SpainAfrica Garcia-Orad, Department of Genetics, Physic Anthropology and Animal Physiology, Faculty of Medicine and Dentistry, University of the Basque Country, Barrio Sarriena s/n, 48940 Leioa, Spain Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5108968 Sat, 06 Aug 2011 05:46:55 +0100 5108968 http://www.medworm.com/index.php?rid=5108969&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnj47762228524h16%2F Conclusion  Nucleoside transporters are frequently expressed in ovarian carcinoma effusions, but their expression generally appears to be unrelated to chemoresponse in this cancer in a cohort of patients treated by platinum-based chemotherapy. The role of ENT2 as a prognostic marker in this disease, as well as the role of these molecules in determining chemoresponse in patients treated by nucleoside analogs, merits further research. Content Type Journal ArticlePages 1-9DOI 10.1007/s00280-011-1716-7Authors Annika J. Bock, Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Montebello, 0424 Oslo, NorwayHiep Phuc Dong, Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Montebello, 0424 Oslo, NorwayClaes G. Tropé, De... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5108969 Sat, 06 Aug 2011 05:46:54 +0100 5108969 http://www.medworm.com/index.php?rid=5103736&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr8738l0195724586%2F Conclusions  These results indicate that individual prediction-based dose adaptation based on ordinal data may be feasible and beneficial. Content Type Journal ArticlePages 1-9DOI 10.1007/s00280-011-1714-9Authors Ines Paule, Université de Lyon, 69622 Lyon, FranceMichel Tod, Université de Lyon, 69622 Lyon, FranceEmilie Hénin, Université de Lyon, 69622 Lyon, FranceBenoit You, Université de Lyon, 69622 Lyon, FranceGilles Freyer, Université de Lyon, 69622 Lyon, FrancePascal Girard, Université de Lyon, 69622 Lyon, France Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5103736 Tue, 02 Aug 2011 06:17:28 +0100 5103736 http://www.medworm.com/index.php?rid=5087235&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn31567880v0m4867%2F Conclusions  Our data provide a comprehensive analysis of the induction profile of atrasentan and its interaction with P-gp and BCRP. The profound induction effects stress the need for thorough assessment of its interaction potential in vivo. Content Type Journal ArticlePages 1-6DOI 10.1007/s00280-011-1715-8Authors Johanna Weiss, Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, GermanyWalter Emil Haefeli, Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5087235 Sat, 30 Jul 2011 15:53:05 +0100 5087235 http://www.medworm.com/index.php?rid=5087236&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw74h54v222328853%2F Conclusion  A causal relationship of observed thromboembolic events to CDDO was considered possible but could not be established. Content Type Journal ArticlePages 1-8DOI 10.1007/s00280-011-1712-yAuthors Giovanna Speranza, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USAMartin E. Gutierrez, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAShivaani Kummar, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USAJohn M. Strong, Laboratory of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USARobert J. Parker, Laboratory of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5087236 Sat, 30 Jul 2011 15:53:04 +0100 5087236 http://www.medworm.com/index.php?rid=5087237&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Few4625l134605541%2F Conclusions  We observe a substantial survival benefit with GTX chemotherapy in our cohort of patients with advanced pancreatic cancer. These findings warrant further investigation of this combination in this patient population. Content Type Journal ArticlePages 1-10DOI 10.1007/s00280-011-1704-yAuthors Ana De Jesus-Acosta, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB I, Room 590, Baltimore, MD 21231, USAGeorge R. Oliver, Cancer Institute of Dallas, Duncanville, TX 75137, USAAmanda Blackford, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB I, Room 590, Baltimore, MD 21231, USAKatharine Kinsman, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB I, Room 590, Ba... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5087237 Thu, 28 Jul 2011 15:59:07 +0100 5087237 http://www.medworm.com/index.php?rid=5087238&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F968376001437n173%2F Conclusions  Triplet of docetaxel, cisplatin, and S-1 is a well-tolerated and highly active regimen for advanced or recurrent gastric cancer. A 60 mg/m2 of cisplatin is as effective as 70 mg/m2 of cisplatin. Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1701-1Authors Wasaburo Koizumi, Department of Gastroenterology/Gastrointestinal Oncology, Kitasato University East Hospital, 2-1-1 Asamizodai, Sagamihara, Kanagawa, 228-8520 JapanNorisuke Nakayama, Division of Gastroenterology, Kanagawa Cancer Center, Kanagawa, JapanSatoshi Tanabe, Department of Gastroenterology/Gastrointestinal Oncology, Kitasato University East Hospital, 2-1-1 Asamizodai, Sagamihara, Kanagawa, 228-8520 JapanTohru Sasaki, Department of Gastroenterology/Gastrointestinal Oncology... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5087238 Wed, 27 Jul 2011 18:48:26 +0100 5087238 http://www.medworm.com/index.php?rid=5087239&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F01x53316555207t8%2F Conclusions  The PBPK model matched the pharmacokinetics in different dosing regimens in adults. Furthermore, the scaling procedure from the adult model to children provides useful predictions for paediatric patients. Comedication with drugs influencing the metabolism and excretion has to be taken into account. This approach could be useful for planning pharmacokinetic studies in children. Content Type Journal ArticlePages 1-9DOI 10.1007/s00280-011-1706-9Authors Gisela Kersting, Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, University of Münster, Münster, GermanyStefan Willmann, Bayer Technology Services GmbH, Competence Centre Systems Biology and Computational Solutions, 51368 Leverkusen, GermanyGudrun Würthwein, Centre for Clinical Trial... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5087239 Tue, 26 Jul 2011 05:47:45 +0100 5087239 http://www.medworm.com/index.php?rid=5087240&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp2rv0146t821300t%2F Conclusion  The FAD regimen had encouraging efficacy with an acceptable toxicity profile in patients with nodal PTCLs. Content Type Journal ArticlePages 1-9DOI 10.1007/s00280-011-1711-zAuthors Xiao-Jian Liu, Department of Medical Oncology, Fudan University Shanghai Cancer center, 270 Dong-An Road, Shanghai, 200032 People’s Republic of ChinaYe Guo, Department of Medical Oncology, Fudan University Shanghai Cancer center, 270 Dong-An Road, Shanghai, 200032 People’s Republic of ChinaYun Fan, Department of Oncology, Zhejiang Provincial Cancer Hospital, 38 Guangji Road, Hangzhou, 310022 People’s Republic of ChinaKang-Sheng Gu, Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022 People’s Republic of Chi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5087240 Tue, 26 Jul 2011 05:47:44 +0100 5087240 http://www.medworm.com/index.php?rid=5063315&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb30x5407777155k4%2F Conclusion  We conclude that KLF4 regulates the cellular sensitivity to cisplatin in hepatocarcinoma stem-like cells and hepatocarcinoma cells by elevating intracellular glutathione levels. Content Type Journal ArticlePages 1-9DOI 10.1007/s00280-011-1708-7Authors Yongsheng Jia, Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730 People’s Republic of ChinaWenjian Zhang, Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, 2 East Yinghuayuan Street, Beijing, 100029 People’s Republic of ChinaHonglin Liu, Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, 2 East Yinghuayuan Street, Beijing, 100029 People’s Republic of ChinaLiang Peng, Institute of Clinical Medical Sciences,... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5063315 Thu, 21 Jul 2011 18:13:27 +0100 5063315 http://www.medworm.com/index.php?rid=5063314&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk816r02g26vn8221%2F Conclusions  Our data demonstrate the feasibility of a sequential approach of cisplatin plus docetaxel followed by single-agent gemcitabine. Weekly administration of platinum-docetaxel is associated with an improved safety profile but lower efficacy than the conventional three-weekly schedule (registration ID 2004-001044-72). Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1710-0Authors Francesco Grossi, Istituto Nazionale per la Ricerca sul Cancro, S.S. Tumori Polmonari, Largo R. Benzi, 10, 16132 Genoa, ItalyFilippo de Marinis, Ospedale S. Camillo Forlanini, Rome, ItalyVittorio Gebbia, Casa di Cura La Maddalena, Palermo, ItalyFerdinando Riccardi, Ospedale Cardarelli, Naples, ItalyOrazio Caffo, Ospedale S. Chiara, Trento, ItalyTeresa Gamucci, P.O. SS. Tri... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5063314 Thu, 21 Jul 2011 18:13:27 +0100 5063314 http://www.medworm.com/index.php?rid=5063316&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg58qr8r07380121k%2F Conclusions  The DVS regimen was active in patients with advanced, previously treated melanoma, with manageable toxicity. The favorable 1-year overall survival and median survival rates suggest that further evaluation of the DVS regimen is warranted. Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1703-zAuthors Zeynep Eroglu, Departments of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USAKevin M. Kong, Departments of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USAJames G. Jakowatz, Departments of Surgery, University of California Irvine Medical Center, Orange, CA 92868, USAWolfram Samlowski, Nevada Cancer Institute, Las Vegas, NV 89135, USAJohn P. Fruehauf, Departments of Medicine, University o... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5063316 Tue, 19 Jul 2011 05:49:25 +0100 5063316 http://www.medworm.com/index.php?rid=5063317&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff4710ppx21k3j133%2F Conclusions  In view of this single-centre experience, we suggest that the treatment of high-grade sarcoma during the third trimester of pregnancy should include an adapted regimen tailored to the pharmacological specificities of the pregnant patients. Content Type Journal ArticlePages 1-11DOI 10.1007/s00280-011-1707-8Authors Olivier Mir, Department of Medicine, Sarcoma Unit, Herault Ward, Institut Gustave Roussy, Paris Sud University, 39, rue Camille Desmoulins, 94800 Villejuif cedex, FranceNarjiss Berrada, Department of Medicine, Sarcoma Unit, Herault Ward, Institut Gustave Roussy, Paris Sud University, 39, rue Camille Desmoulins, 94800 Villejuif cedex, FranceJulien Domont, Department of Medicine, Sarcoma Unit, Herault Ward, Institut Gustave Roussy, Paris Sud Univer... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5063317 Tue, 19 Jul 2011 05:49:24 +0100 5063317 http://www.medworm.com/index.php?rid=5038056&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff14vn2l5084012l2%2F Conclusions  This Phase I trial concludes that gemcitabine 500 mg/m2 on days 1 and 4 of each 21-day cycle is the maximum tolerated dose when combined with standard CHOP chemotherapy with G-CSF support for intermediate grade NHL. Content Type Journal ArticlePages 1-6DOI 10.1007/s00280-011-1702-0Authors John L. Reagan, Department of Hematology/Oncology, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USAAlan Rosmarin, Department of Hematology/Oncology, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USAJames N. Butera, Department of Hematology/Oncology, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USAAhmed Nadeem, Department of Hematology/Oncology, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USAFred J. ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5038056 Thu, 14 Jul 2011 16:52:00 +0100 5038056 http://www.medworm.com/index.php?rid=5030060&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F97jv2723604278j6%2F Conclusions  The GCD combination is an active and well-tolerated regimen in patients with chemotherapy-naive locally advanced or metastatic TCC and merits to be further investigated. Content Type Journal ArticlePages 1-6DOI 10.1007/s00280-011-1694-9Authors Ioannis Boukovinas, Hellenic Oncology Research Group (HORG), 55 Lomvardou str, 11740 Athens, GreeceNikolaos Androulakis, Hellenic Oncology Research Group (HORG), 55 Lomvardou str, 11740 Athens, GreeceNikolaos Kentepozidis, Hellenic Oncology Research Group (HORG), 55 Lomvardou str, 11740 Athens, GreeceAris Polyzos, Hellenic Oncology Research Group (HORG), 55 Lomvardou str, 11740 Athens, GreecePavlos Papakotoulas, Hellenic Oncology Research Group (HORG), 55 Lomvardou str, 11740 Athens, GreeceNikolaos Ziras, Hellenic O... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5030060 Tue, 12 Jul 2011 06:04:23 +0100 5030060 http://www.medworm.com/index.php?rid=5020065&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc15465gn0wp66112%2F Conclusion  Trabectedin did not prolong the QTc interval. Safety and pharmacokinetic profiles of trabectedin were similar to that observed in other ovarian and breast cancer studies. Content Type Journal ArticlePages 1-10DOI 10.1007/s00280-011-1697-6Authors R. Thertulien, Cancer Centers of North Carolina-Asheville, 20 Medical Park Drive, Asheville, NC 28803, USAG. M. Manikhas, City Clinical Oncology Dispensary, St. Petersburg, RussiaL. Y. Dirix, AZ Sint-Augustinus, Oncologisch Centrum, Wilrijk, BelgiumJ. B. Vermorken, Universitair Ziekenhuis Antwerpen, Edegem, BelgiumK. Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaM. M. Jain, Ruby Hall Clinic, Pune, IndiaJ. J. Jiao, Johnson & Johnson Pharmaceutical Research & Development, L.L.C... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5020065 Fri, 08 Jul 2011 06:29:08 +0100 5020065 http://www.medworm.com/index.php?rid=5020066&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0772l14522836562%2F Conclusions  Sorafenib as continuous oral treatment in combination with gemcitabine and cisplatin demonstrated an acceptable safety profile. No clinically relevant pharmacokinetic interaction was detected. Preliminary antitumor activity, pharmacokinetic, and safety data support the recommendation of 400 mg sorafenib twice daily in combination with cisplatin and gemcitabine to be further evaluated in clinical studies. Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1685-xAuthors B. Schultheis, Department of Haematology and Medical Oncology, University of Bochum (Marienhospital Herne), Hoelkeskampring 40, 44625 Herne, GermanyG. Kummer, Department of Haematology and Medical Oncology, University of Bochum (Marienhospital Herne), Hoelkeskampring 40, 4462... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=5020066 Thu, 07 Jul 2011 05:51:24 +0100 5020066 http://www.medworm.com/index.php?rid=4993539&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw1670pq336278023%2F Conclusion  Our results demonstrate that matrine inhibits the proliferation and induces apoptosis of human osteosarcoma cells in vitro and in vivo. The induction of apoptosis appears to occur through the upregulation of Fas/FasL and Bax, downregulation of Bcl-2, and activation of caspase-3, -8, and -9, which then trigger major apoptotic cascades. Content Type Journal ArticlePages 1-15DOI 10.1007/s00280-011-1699-4Authors Cheng Zhen Liang, Department of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, #88 Jie Fang Road, Hangzhou, 310009 Zhejiang, People’s Republic of ChinaJia Kai Zhang, Department of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, #88 Jie Fang Road, Hangzhou, 310009 Zhejiang, People’s Rep... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4993539 Wed, 29 Jun 2011 15:50:40 +0100 4993539 http://www.medworm.com/index.php?rid=4993541&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm68011x7147r7051%2F This article reviews current knowledge on predictive value of protein Tau in response to taxanes. Better understanding of its role may facilitate patients selection to this sort of treatment and lead to treatment optimization. Content Type Journal ArticlePages 1-5DOI 10.1007/s00280-011-1696-7Authors Marta Smoter, Klinika Onkologii Kobiet, Wojskowy Instytut Medyczny, Ul. Szaserów 128, 04-141 Warszawa, PolandLubomir Bodnar, Klinika Onkologii Kobiet, Wojskowy Instytut Medyczny, Ul. Szaserów 128, 04-141 Warszawa, PolandRenata Duchnowska, Klinika Onkologii Kobiet, Wojskowy Instytut Medyczny, Ul. Szaserów 128, 04-141 Warszawa, PolandRafał Stec, Klinika Onkologii Kobiet, Wojskowy Instytut Medyczny, Ul. Szaserów 128, 04-141 Warszawa, PolandBartłomiej Grala, Zakład Patomorfologii, W... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4993541 Tue, 28 Jun 2011 15:49:57 +0100 4993541 http://www.medworm.com/index.php?rid=4993540&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe08406t725706716%2F Conclusions  Both treatments exerted antitumor effects in vivo, and combined use of the two approaches produced more powerful antitumor effects. Synergistic effects of combined treatment in VEGF expression may contribute to the mechanisms of the strong antitumor effects. Content Type Journal ArticlePages 1-9DOI 10.1007/s00280-011-1698-5Authors Xiaoling Ding, Department of Gastroenterology, Affiliated Hospital of Nantong University, 20 Xisi Road, 226001 Nangtong, Jiangsu, People’s Republic of ChinaXiaorong Zhou, Department of Microbiology and Immunology, Medical school of Nantong University, 19 Qixiu Road, 226001 Nantong, Jiangsu, People’s Republic of ChinaHaifeng Zhang, Department of Gastroenterology, Affiliated Hospital of Nantong University, 20 Xisi Road, 22600... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4993540 Tue, 28 Jun 2011 15:49:57 +0100 4993540 http://www.medworm.com/index.php?rid=4985519&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2v46307489710w70%2F Conclusion  These results indicate that FOLFOX induces ROS in patients and that ROS-generating mechanisms interact. Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1700-2Authors Shoaib Afzal, Laboratory of Clinical Pharmacology Q7642, Rigshospitalet, 20 Tagensvej, 2200 Copenhagen, DenmarkSøren Astrup Jensen, Department of Oncology, Rigshospitalet, Copenhagen, DenmarkJens Benn Sørensen, Department of Oncology, Rigshospitalet, Copenhagen, DenmarkTrine Henriksen, Laboratory of Clinical Pharmacology Q7642, Rigshospitalet, 20 Tagensvej, 2200 Copenhagen, DenmarkAllan Weimann, Laboratory of Clinical Pharmacology Q7642, Rigshospitalet, 20 Tagensvej, 2200 Copenhagen, DenmarkHenrik Enghusen Poulsen, Laboratory of Clinical Pharmacology Q7642, Rigshospitalet, 20 Tagens... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4985519 Mon, 27 Jun 2011 18:11:32 +0100 4985519 http://www.medworm.com/index.php?rid=4985518&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa10254836w553327%2F Conclusions  This trial indicates the lack of effectiveness of imatinib in unselected patients with thymic epithelial tumors. Nevertheless, imatinib may represent a valuable option in selected patients with TETs, such as those harboring the V560del c-KIT mutation. Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1690-0Authors Giovannella Palmieri, Molecular and Clinical Endocrinology and Oncology Department, University Federico II, Via Pansini 5, 80128 Naples, ItalyMirella Marino, Department of Pathology, Regina Elena National Cancer Institute, Rome, ItalyCarlo Buonerba, Molecular and Clinical Endocrinology and Oncology Department, University Federico II, Via Pansini 5, 80128 Naples, ItalyPiera Federico, Molecular and Clinical Endocrinology and Oncology Dep... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4985518 Mon, 27 Jun 2011 18:11:32 +0100 4985518 http://www.medworm.com/index.php?rid=4977347&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc373x3224l4n6150%2F Conclusions  Satraplatin penetration into CSF is similar to that of carboplatin and cisplatin, despite its greater lipophilicity. The development of a phase I trial of satraplatin for refractory childhood solid tumors including brain tumors is in progress. Content Type Journal ArticlePages 1-6DOI 10.1007/s00280-011-1659-zAuthors Leigh Marcus, National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Building 10-CRC, Room 1-5742, Bethesda, MD 20892-1101, USARobert Murphy, National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Building 10-CRC, Room 1-5742, Bethesda, MD 20892-1101, USAElizabeth Fox, Children’s Hospital of Philadelphia, 3615 Civic Center Blvd, Philadelphia, PA 19104, USACynthia McCully, National Cancer Institute, Pediatric O... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4977347 Sat, 25 Jun 2011 15:54:22 +0100 4977347 http://www.medworm.com/index.php?rid=4977349&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F412q4230377q118l%2F Conclusions  Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant. Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary. Content Type Journal ArticlePages 1-9DOI 10.1007/s00280-011-1693-xAuthors Paul Hamberg, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, P.O. Box 5201, 3008 AE Rotterdam, The NetherlandsMargaret M. Woo, Novartis Pharmaceutical Corporation, Florham Park, NJ, USALin-Chi Chen, Nevada Cancer Institute, Las Vegas, NV, USAJaap Ve... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4977349 Sat, 25 Jun 2011 15:54:21 +0100 4977349 http://www.medworm.com/index.php?rid=4977350&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh4w5805t7691048w%2F Conclusions  Our finding suggested that endostar given simultaneously with or following gemcitabine might be optimal to enhance the antitumor effect. Content Type Journal ArticlePages 1-8DOI 10.1007/s00280-011-1695-8Authors Xing-Chen Peng, Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041 Sichuan Province, ChinaMeng Qiu, Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041 Sichuan Province, ChinaMeng Wei, Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherap... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4977350 Sat, 25 Jun 2011 05:42:42 +0100 4977350 http://www.medworm.com/index.php?rid=4969912&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flhk77u9004468616%2F Conclusions  E6201 exhibited high clearance, high to moderate distribution, and fast elimination in preclinical species. In vitro results suggested that E6201 has low risk of drug–drug interactions due to CYP inhibition and induction in humans. In the first-in-man study, E6201 exhibited high clearance, which was well predicted by allometric scaling. Content Type Journal ArticlePages 1-9DOI 10.1007/s00280-011-1687-8Authors Vipul Kumar, Non-clinical Drug Development, Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USAEdgar L. Schuck, DMPK-Andover, Biopharmaceutical Assessments CFU, Eisai Inc., Andover, MA 01810, USARobert D. Pelletier, DMPK-Andover, Biopharmaceutical Assessments CFU, Eisai Inc., Andover, MA 01810, USANadia Farah, DMPK-Andover, Biopharm... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4969912 Wed, 22 Jun 2011 16:01:50 +0100 4969912 http://www.medworm.com/index.php?rid=4969913&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdl23v261505142t4%2F Conclusions  Belotecan and cisplatin combination therapy showed significant efficacy in ED SCLC with improved non-hematologic toxicities. Content Type Journal ArticlePages 1-6DOI 10.1007/s00280-011-1689-6Authors Junshik Hong, Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science School of Medicine, 21 Namdongdae-ro 774-gil, Guwol 1-dong, Namdong-gu, Incheon, 405-760 Republic of KoreaMinkyu Jung, Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Science School of Medicine, 21 Namdongdae-ro 774-gil, Guwol 1-dong, Namdong-gu, Incheon, 405-760 Republic of KoreaYu Jin Kim, Department of Internal Medicine, Gachon University Gil Hospital, Gachon University of Medicine and Scien... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4969913 Tue, 21 Jun 2011 16:42:40 +0100 4969913 http://www.medworm.com/index.php?rid=4969914&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl11xt544611331m5%2F Conclusions  Bosutinib 200–600 mg with food was safe and well tolerated. Under fed conditions, bosutinib exposures were linear and dose proportional, and C max increased by ~1.5-fold. The t 1/2 supported a once-daily dosing regimen. Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1688-7Authors Richat Abbas, Department of Clinical Pharmacology, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USABruce A. Hug, Department of Clinical Pharmacology, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USACathie Leister, Department of Clinical Pharmacology, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USAMyriam El Gaaloul, Department of Clinical Pharmacology, Pfizer Global Research and Development, Paris, FranceStephan Chalon, Department of ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4969914 Tue, 21 Jun 2011 16:42:39 +0100 4969914 http://www.medworm.com/index.php?rid=4946295&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq509075447460072%2F In conclusion, the current study demonstrated that the reproductive toxicity caused by CP may be prevented by ML treatment. Thus, it was judged that co-administration of ML with CP may be useful to attenuate the negative effects of CP on male reproductive system. Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1692-yAuthors Ali Beytur, Faculty of Medicine, Department of Urology, University of Inonu, 44280 Malatya, TurkeyOsman Ciftci, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, University of Inonu, 44280 Malatya, TurkeyFatih Oguz, Faculty of Medicine, Department of Urology, University of Inonu, 44280 Malatya, TurkeyHakan Oguzturk, Faculty Medicine, Department of Emergency Medicine, University of Inonu, 44280 Malatya, TurkeyFethi Yılmaz, Elazig School ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4946295 Fri, 17 Jun 2011 11:58:46 +0100 4946295 http://www.medworm.com/index.php?rid=4946296&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0526542223l42733%2F Conclusions  This study indicates that CSF concentrations of erlotinib depend on its plasma concentration. As seen in this patient, high CSF concentrations of erlotinib can be achieved by high-dose administration, and this finding suggests the efficacy of high-dose administration, especially to refractory CNS metastases of NSCLC patients. Content Type Journal ArticlePages 1-4DOI 10.1007/s00280-011-1691-zAuthors Yosuke Togashi, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507 JapanKatsuhiro Masago, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507 JapanMasahide Fukudo, Department of Pharmacy, Graduate School... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4946296 Fri, 17 Jun 2011 11:58:44 +0100 4946296 http://www.medworm.com/index.php?rid=4936250&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa16h962n7243k073%2F Conclusion  The present study demonstrates that DMF selectively enhances TRAIL-induced apoptosis by ROS-stimulated ER-stress triggering CHOP-mediated DR5 upregulation in HCC. Content Type Journal ArticlePages 1-12DOI 10.1007/s00280-011-1686-9Authors Jian-Feng Yang, Medical College, Hunan Normal University, Changsha, 410013 ChinaJian-Guo Cao, Medical College, Hunan Normal University, Changsha, 410013 ChinaLi Tian, Medical College, Hunan Normal University, Changsha, 410013 ChinaFei Liu, Medical College, Hunan Normal University, Changsha, 410013 China Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4936250 Fri, 10 Jun 2011 06:34:30 +0100 4936250 http://www.medworm.com/index.php?rid=4913233&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc740552308725155%2F Conclusions  Perifosine is active in select RCC lines, abrogating the induction of AKT phosphorylation mediated by mTOR inhibition. Combined mTOR and AKT inhibition resulted in the modulation of pro-angiogenesis pathways, providing a basis for future investigations. Content Type Journal ArticlePages 1-10DOI 10.1007/s00280-011-1684-yAuthors William S. Holland, University of California, Davis Cancer Center, 4501 X Street, Suite, 3016, Sacramento, CA 95817, USAClifford G. Tepper, University of California, Davis Cancer Center, 4501 X Street, Suite, 3016, Sacramento, CA 95817, USAJose E. Pietri, University of California, Davis Cancer Center, 4501 X Street, Suite, 3016, Sacramento, CA 95817, USADanielle C. Chinn, University of California, Davis Cancer Center, 4501 X Street,... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4913233 Sun, 05 Jun 2011 05:46:48 +0100 4913233 http://www.medworm.com/index.php?rid=4903692&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn0nq508846815p65%2F Conclusions  These results support the clinical assessment of SIM010603 as a therapeutic agent for cancer. Content Type Journal ArticlePages 1-11DOI 10.1007/s00280-011-1681-1Authors Dongchun Wang, Jiangsu Center for Drug Screening, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009 ChinaFeng Tang, Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Nanjing, 210042 ChinaSen Wang, Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Nanjing, 210042 ChinaZhenzhou Jiang, Jiangsu Center for Drug Screening, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009 ChinaLuyong Zhang, Jiangsu Center for Drug Screening, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009 China Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Pr... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4903692 Fri, 03 Jun 2011 06:01:11 +0100 4903692 http://www.medworm.com/index.php?rid=4903693&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm2x078218k546020%2F Abstract  It is well established that antibodies to vascular endothelial growth factor (VEGF) in combination with chemotherapeutic agents produce synergistic cytotoxicity in a range of cancer. In this review article, it has been analyzed whether the so-called vascular normalization of abnormal tumor blood vessels as an effect of VEGF inhibition in association with chemotherapeutic agents in the treatment of tumors produces a real benefit. Literature data show that the process of normalization of the structure of tumor blood vessels is not always accompanied with a real benefit. In fact as in the case of cerebral tumors, the process of normalization may induce a re-establishment of the low permeability characteristics of normal brain microvasculature, preventing the delivery... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4903693 Fri, 03 Jun 2011 06:01:10 +0100 4903693 http://www.medworm.com/index.php?rid=4903694&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F534271v32m108717%2F Conclusion  The MTD of AZD4877 given as a 1-h iv infusion on days 1, 8, and 15 of a 28-day cycle was 30 mg. At the selected 25 mg dose, AZD4877 had an acceptable safety profile. Content Type Journal ArticlePages 1-8DOI 10.1007/s00280-011-1667-zAuthors J. R. Infante, Sarah Cannon Research Institute, Nashville, TN, USAR. Kurzrock, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USAJ. Spratlin, University of Colorado Cancer Center, Denver, CO, USAH. A. Burris, Sarah Cannon Research Institute, Nashville, TN, USAS. G. Eckhardt, University of Colorado Cancer Center, Denver, CO, USAJ. Li, AstraZeneca Pharmaceuticals, Wilmington, DE, USAK. Wu, AstraZeneca Pharmaceuticals, Waltham, MA, USAJ. M. Skolnik, AstraZeneca Pha... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4903694 Fri, 03 Jun 2011 06:01:09 +0100 4903694 http://www.medworm.com/index.php?rid=4903696&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F097378715322077k%2F Conclusion  Lung cancer cells with high level of CLU have reduced chemosensitivity. High level of CLU may result in migratory inhibition and thus favorable prognosis in lung cancer. Content Type Journal ArticlePages 1-10DOI 10.1007/s00280-011-1682-0Authors Ching-Yuan Cheng, Division of General Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, 135 Nanxiao St., Changhua City, Changhua County 500, TaiwanShur-Hueih Cherng, Department of Biotechnology, Hung Kuang University, 34 Chung-Chie Rd, Sha Lu, Taichung City, 443 TaiwanWen-Jun Wu, Institute of Medicine, Chung Shan Medical University, Research Building Room 702, No. 110, Sec. 1, Jianguo N. Road, Taichung City, 402 TaiwanTsung-Ying Yang, Institute of Medicine, Chung Shan Medical University, Research... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=4903696 Wed, 01 Jun 2011 06:00:37 +0100 4903696